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Abstract
The problem of evaluating an individual’s risk of drug consumption and misuse is
highly important. An online survey methodology was employed to collect data
including Big Five personality traits (NEO-FFI-R), impulsivity (BIS-11), sensation
seeking (ImpSS), and demographic information. The data set contained information
on the consumption of 18 central nervous system psychoactive drugs. Correlation
analysis demonstrated the existence of groups of drugs with strongly correlated
consumption patterns. Three correlation pleiades were identified, named by the
central drug in the pleiade: ecstasy, heroin, and benzodiazepines pleiades. An
exhaustive search was performed to select the most effective subset of input features
and data mining methods to classify users and non-users for each drug and pleiad. A
number of classification methods were employed (decision tree, random forest,
k-nearest neighbors, linear discriminant analysis, Gaussian mixture, probability
density function estimation, logistic regression and na¨ıve Bayes) and the most effective
classifier was selected for each drug. The quality of classification was surprisingly high
with sensitivity and specificity (evaluated by leave-one-out cross-validation) being
greater than 70% for almost all classification tasks. The best results with sensitivity
and specificity being greater than 75% were achieved for cannabis, crack, ecstasy, legal
highs, LSD, and volatile substance abuse (VSA).
Introduction
After Popper, it is a commonplace opinion in philosophy of science that the ‘value’ of
definitions besides mathematics is generally low. Nevertheless, for many more practical
needs, from jurisprudence to health planning, the definitions are necessary to impose
theoretical boundaries of a subject despite of their incompleteness and temporariness.
This highly applies to definitions of drugs and drug use. Following the standard
definitions [1], a drug is a ‘chemical that influences biological function (other than by
providing nutrition or hydration)’. A psychoactive drug is a ‘drug whose influence is in
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a part on mental functions’. An abusable psychoactive drug is a ‘drug whose mental
effects are sufficiently pleasant or interesting or helpful that some people choose to
take it for a reason other than to relieve a specific malady’. In our study we use the
term ‘drug’ for abusable psychoactive drug regardless of whether it’s illicit or not.
Drug use is a risk behaviour that does not happen in isolation; it constitutes an
important factor for increasing risk of poor health, along with earlier mortality and
morbidity, and has significant consequences for society [2, 3]. Drug consumption and
addiction constitutes a serious problem globally. It includes numerous risk factors,
which are defined as any attribute, characteristic, or event in the life of an individual
that increases the probability of drug consumption. A number of factors are correlated
with initial drug use including psychological, social, individual, environmental, and
economic factors [4–6]. These factors are likewise associated with a number of
personality traits [7, 8]. While legal drugs such as sugar, alcohol and tobacco are
probably responsible for far more premature death than illegal recreational drugs [9],
the social and personal consequences of recreational drug use can be highly
problematic [10].
Psychologists have largely agreed that the personality traits of the Five Factor
Model (FFM) are the most comprehensive and adaptable system for understanding
human individual differences [11]. The FFM comprises Neuroticism (N), Extraversion
(E), Openness to Experience (O), Agreeableness (A), and Conscientiousness (C).
A number of studies have illustrated that personality traits are associated to drug
consumption. Roncero et al [12] highlighted the importance of the relationship
between high N and the presence of psychotic symptoms following cocaine-induced
drug consumption. Vollrath & Torgersen [13] observed that the personality traits of N,
E, and C are highly correlated with hazardous health behaviours. A low score of C,
and high score of E or high score of N correlate strongly with multiple risky health
behaviours. Flory et al [14] found alcohol use to be associated with lower A and C,
and higher E. They found also that lower A and C, and higher O are associated with
marijuana use. Sutina et al [3] demonstrated that the relationship between low C and
drug consumption is moderated by poverty; low C is a stronger risk factor for illicit
drug usage among those with relatively higher socioeconomic status. They found that
high N, and low A and C are associated with higher risk of drug use (including
cocaine, crack, morphine, codeine, and heroin). It should be mentioned that high N is
positively associated with many other addictions like Internet addiction, exercise
addiction, compulsive buying, and study addiction [15].
An individual’s personality profile plays a role in becoming a drug user.
Terracciano et al [16] demonstrated that the personality profiles for the users and
non-users of nicotine, cannabis, cocaine, and heroin are associated with a FFM of
personality samples from different communities. They also highlight the links between
the consumption of these drugs and low C. Turiano et al [17] found a positive
correlation between N and O, and drug use, while, increasing scores for C and A
decreases risk of drug use. Previous studies demonstrated that participants who use
drugs including alcohol and nicotine have a strong positive correlation between A and
C and a strong negative correlation for each of these factors with N [18, 19]. Three
high-order personality traits are proposed as endophenotypes for substance use
disorders: Positive Emotionality, Negative Emotionality, and Constraint [20].
The statistical characteristics of groups of drug users and non-users have been
studied by many authors (see, for example, Terracciano et al [16]). They found that
the personality profile for the users and non-users of tobacco, marijuana, cocaine, and
heroin are associated with a higher score on N and a very low score for C. Sensation
seeking is also higher for users of recreational drugs [21]. The problem of risk
evaluation for individuals is much more complex. This was explored very recently by
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Yasnitskiy et al [22], Valeroa et al [23] and Bulut & Bucak [24]. Both individual and
environmental factors predict substance use and different patterns of interaction
among these factors may have different implications [25]. Age is a very important
attribute for diagnosis and prognosis of substance use disorders. In particular, early
adolescent onset of substance use is a robust predictor of future substance use
disorders [26].
Valeroa et al [23] evaluated the individual risk of drug consumption for alcohol,
cocaine, opiates, cannabis, ecstasy and amphetamines. Input data were collected using
the Spanish version of the Zuckerman-Kuhlman Personality Questionnaire (ZKPQ).
Two samples were used in this study. The first one consisted of 336 drug dependent
psychiatric patients of one hospital. The second sample included 486 control
individuals. The authors used a decision tree as a tool to identify the most informative
attributes. The sensitivity of 40% and the specificity of 94% were achieved for the
training set. The main purpose of this research was to test if predicting drug
consumption was possible and to identify the most informative attributes using data
mining methods. The decision tree methods were applied to explore the differential
role of personality profiles in drug consumer and control individuals. The two
personality factors, Neuroticism and anxiety and the ZKPQ’s Impulsivity, were found
to be most relevant for drug consumption prediction. Low sensitivity (40%) does not
provide application of this decision tree to real life problems.
In our study we tested the associations with personality traits for different types of
drugs separately using the Revised NEO Five-Factor Inventory (NEO-FFI-R) [28], the
Barratt Impulsiveness Scale version 11 (BIS-11) [29], and the Impulsivity
Sensation-Seeking scale (ImpSS) [30] to assess impulsivity and sensation-seeking
respectively.
Bulut & Bucak [24] detected a risk rate for teenagers in terms of percentage who
are at high risk without focusing on specific addictions. The attributes were collected
by an original questionnaire, which included 25 questions. The form was filled in by
671 students. The first 20 questions asked about the teenagers’ financial situation,
temperament type, family and social relations, and cultural preferences. The last five
questions were completed by their teachers and concerned the grade point average of
the student for the previous semester according to a 5-point grading system, whether
the student had been given any disciplinary punishment so far, if the student had
alcohol problems, if the student smoked cigarettes or used tobacco products, and
whether the student misused substances. In Bulut et al’s study there are five risk
classes as outputs. The authors diagnosed teenagers risk to be a drug abuser using
seven types of classification algorithms: k-nearest neighbor, ID3 and C4.5 decision tree
based algorithms, na¨ıve Bayes classifier, na¨ıve Bayes/decision trees hybrid approach,
one-attribute-rule, and projective adaptive resonance theory. The classification
accuracy of the best classifier was reported as 98%.
Yasnitskiy et al [22], attempted to evaluate the individual’s risk of illicit drug
consumption and to recommend the most efficient changes in the individual’s social
environment to reduce this risk. The input and output features were collected by an
original questionnaire. The attributes consisted of: level of education, having friends
who use drugs, temperament type, number of children in the family, financial situation,
alcohol drinking and smoking, family relations (cases of physical, emotional and
psychological abuse, level of trust and happiness in the family). There were 72
participants. A neural network model was used to evaluate the importance of
attributes for diagnosis of the tendency to drug addiction. A series of virtual
experiments was performed for several test patients (drug users) to evaluate how it is
possible to control the propensity for drug addiction. The most effective change of
social environment features was predicted for each patient. The recommended changes
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depended on the personal profile, and significantly varied for different patients. This
approach produced individual bespoke advice for decreasing drug dependence.
In our study, the database was collected by an anonymous online survey
methodology by Elaine Fehrman yielding 2051 respondents. The database is available
online [27]. Twelve attributes are known for each respondent: personality
measurements which include N, E, O, A, and C scores from NEO-FFI-R, impulsivity
(Imp.) from (BIS-11), sensation seeking (SS) from (ImpSS), level of education (Edu.),
age, gender, country of residence, and ethnicity. The data set contains information on
the consumption of 18 central nervous system psychoactive drugs including alcohol,
amphetamines, amyl nitrite, benzodiazepines, cannabis, chocolate, cocaine, caffeine,
crack, ecstasy, heroin, ketamine, legal highs, LSD, methadone, magic mushrooms
(MMushrooms), nicotine, and Volatile Substance Abuse (VSA), and one fictitious drug
(Semeron) which was introduced to identify over-claimers. Participants selected for
each drug either they never used this drug, used it over a decade ago, or in the last
decade, year, month, week, or day.
Participants were asked about substances, which were classified as central nervous
system depressants, stimulants, or hallucinogens. The depressant drugs comprised
alcohol, amyl nitrite, benzodiazepines, tranquilizers, gamma-hydroxybutyrate solvents
and inhalants, and opiates such as heroin and methadone/prescribed opiates. The
stimulants consisted of amphetamines, nicotine, cocaine powder, crack cocaine,
caffeine, and chocolate. Although chocolate contains caffeine, data for chocolate was
measured separately, given that it may induce parallel psychopharmacological and
behavioural effects in individuals congruent to other addictive substances [31]. The
hallucinogens included cannabis, ecstasy, ketamine, LSD, and magic mushrooms.
Legal highs such as mephedrone, salvia, and various legal smoking mixtures were also
measured.
We use four different definitions of ‘drug users’ based on the recency of use. Firstly,
two isolated categories (‘Never used’ and ‘Used over a decade ago’) are placed into the
class of non-users, and all other categories are merged to form the class of users.
Secondly, we merge the categories ‘Used in last decade’, ‘Used over a decade ago’ and
‘Never used’ into the group of non-users and place four other categories (‘Used in last
year-month-week-day’) into group of users. This classification is called ‘year-based’
one. Also ‘month-based’ and ‘week-based’ user/non-user separations are considered.
The objective of the study was to assess the potential effect of big five personality
traits, impulsivity, sensation-seeking, and demographic data on drug consumption for
different drugs, groups of drugs and for different definitions of drug users. The study
had two purposes: (i) to identify the association of personality profiles (i.e.
NEO-FFI-R) with drug consumption and (ii) to predict the risk of drug consumption
for each individual according to their personality profiles. Part of the results was
presented in the preprint [32].
The sample was created by an anonymous online survey. It was found to be biased
when compared with the general population, which was indicated from comparison to
the data published by Egan, et al [33] and Costa Jr & McCrae [28]. Such a bias is
usual for clinical cohorts [16, 34].
Our study reveals that the personality profiles are strongly associated with
belonging to groups of the users and non-users of the 18 drugs. For analysis, we use
the following subdivision of the sample T-score: the interval 44-49 indicates a
moderately low score, (−), the interval 49-51 indicates a neutral score (0), and the
interval 51-56 indicates a moderately high (+) score. We found that the N and O
scores of drug users of all 18 drugs are moderately high (+) or neutral (0), except for
crack usage for the week-based classification, for which the O score is moderately low
(−). The A and C scores are moderately low (−) or neutral (0) for all groups of drug
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users and all user/non-user separations. For most groups of illicit drug users the A
and C scores are moderately low (−) except two exclusions: the A score is neutral (0)
in the year-based classification for LSD users and in the week-based classification for
LSD and magic mushrooms users. The A and C scores for groups of legal drugs users
(i.e. alcohol, chocolate, caffeine, and nicotine) are neutral (0), apart from nicotine
users, whose C score is moderately low (−) for all bases of user/non-user separation.
The impact of the E score is drug specific. For example, for the week-based
user/non-user separation the E scores are:
• The E score of users is moderately low (−) for amphetamines, amyl nitrite,
benzodiazepines, heroin, ketamine, legal highs, methadone, and crack;
• The E score of users is moderately high (+) for cocaine, ecstasy, LSD, magic
mushrooms, and VSA;
• The E score of users is neutral (0) for alcohol, caffeine, chocolate, cannabis, and
nicotine.
For more details see Section ‘Comparison of personality traits means for drug users
and non-users’ in ‘Results’.
Usage of some drugs are significantly correlated. The structure of these correlations
is analysed in Section ‘Correlation between usage of different drugs’. Two correlation
measures are utilised: the Pearson Correlation Coefficient (PCC) and the Relative
Information Gain (RIG). We found three groups of drugs with highly correlated use.
The central element is clearly identified for each group. These centres are: heroin,
ecstasy, and benzodiazepines. It means that the drug consumption has a ‘modular
structure’. The modular structure has clear reflection in the correlation graph. The
idea to merge the correlated attributes into ‘modules’ called as correlation pleiades is
popular in biology [35–37].
The concept of correlation pleiades was introduced in biostatistics in 1931 [35].
They were used for identification of the modular structure in evolutionary
physiology [35–38]. According to Berg [37], correlation pleiades are clusters of
correlated traits. In our approach, we distinguish the core and the peripheral elements
of correlation pleiades and allow different pleiads to have small intersections in their
periphery. ‘Soft’ clustering algorithms relax the restriction that each data object is
assigned to only one cluster (like probabilistic [39] or fuzzy [40] clustering). See the
book of R. Xu and D. Wunsch [41] for the modern review of hard and soft clustering.
We refer to [42] for a discussion of clustering in graphs with intersections .
The three groups of correlated drugs centered around heroin, ecstasy, and
benzodiazepines are defined for the decade-, year-, month-, and week-based
classifications:
• The heroin pleiad includes crack, cocaine, methadone, and heroin;
• The ecstasy pleiad consists of amphetamines, cannabis, cocaine, ketamine, LSD,
magic mushrooms, legal highs, and ecstasy;
• The benzodiazepines pleiad contains methadone, amphetamines, cocaine, and
benzodiazepines.
Analysis of the intersections between correlation pleiads of drugs can generate
important question and hypotheses:
• Why is cocaine a peripherical member of all pleiads?
• Why does methadone belong to the periphery of both the heroin and
benzodiazepines pleiades?
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• Do these intersections reflect the structure of individual drug consumption or the
structure of the groups of drug consumers?
Correlation analysis of the decade-based classification problems demonstrates that
the consumption of legal drugs (i.e. alcohol, chocolate and caffeine) is not correlated
with consumption of other drugs. The consumptions of seven illicit drugs (i.e.
amphetamines, cannabis, cocaine, ecstasy, legal highs, LSD, and mushrooms) are
symmetrically correlated (when the correlations are measured by relative information
gain, which is not symmetric a priori). There are also many strongly asymmetric
correlations. For example, knowledge of amphetamines, cocaine, ecstasy, legal highs,
LSD, and magic mushroom consumption is useful for the evaluation of ketamine
consumption, but on the other hand, knowledge of ketamine consumption is
significantly less useful for the evaluation of usage of the drugs listed above.
In this study, we evaluated the individual drug consumption risk separately, for
each drug and pleiad of drugs. We also analyzed interrelations between the individual
drug consumption risks for different drugs. We applied several data mining
approaches: decision tree, random forest, k-nearest neighbors, linear discriminant
analysis, Gaussian mixture, probability density function estimation, logistic regression
and na¨ıve Bayes. The quality of classification was surprisingly high. We tested all the
classifiers by Leave-One-Out Cross Validation. The best results with sensitivity and
specificity being greater than 75% were achieved for cannabis, crack, ecstasy, legal
highs, LSD, and VSA. Sensitivity and specificity greater than 70% were achieved for
the following drugs: amphetamines, amyl nitrite, benzodiazepines, chocolate, caffeine,
heroin, ketamine, methadone and nicotine. The poorest result was obtained for
prediction of alcohol consumption. An exhaustive search was performed to select the
most effective subset of input features, and data mining methods to classify users and
non-users for each drug.
Users are defined for each correlation pleiad of drugs as users of any of the drug
from the pleiade. We consider the classification problem for drug pleiades for the
decade-, year-, month-, and week-based user/non-user separations. These problems are
much better balanced for short periods (the week-based user definition) than the
classification problems for separate drugs. For example, there are 184 users for the
heroin pleiad but only 29 heroin users in the database for the week-based definition of
users. The quality of classification is high. For example, for the month-based
user/non-user separation of the heroin pleiad consumption, the best classifier is a
decision tree with five features and sensitivity 74.18% and specificity 74.11%. A
decision tree with seven attributes is the best classifier for the year-based classification
problem of the ecstasy pleiad users/non-users and has sensitivity 80.65% and
specificity 80.72%. In the week-based separation of the benzodiazepines pleiad
users/non-users, the best classifier is a decision tree with five features, sensitivity
75.10%, and specificity 75.76%.
The creation of classifiers provided the capability to evaluate the risk of drug
consumption in relation to individuals. The risk map is a useful tool for data
visualisation and for the generation of hypotheses for further study (see Section ‘Risk
evaluation for the decade-based user/non-user separation’).
The main results of the work are:
• Presentation and descriptive analysis of a database with information of 1885
respondents and usage of 18 drugs.
• Demonstration that the personality traits (five factor model, impulsivity, and
sensation seeking) together with simple demographic data give the possibility of
predicting the risk of consumption of individual drugs with sensitivity and
specificity above 70% for most drugs.
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• The best classifiers and most significant predictors are found for each individual
drug in question.
• Revelation of three correlation pleiads of drugs, that are the clusters of drugs
with correlated consumption centered around heroin, ecstasy, and
benzodiazepines.
• The best robust classifiers and most significant predictors are found for use of
pleiads of drugs.
• The risk map technology is developed for the visualization of the probability of
drug consumption.
Materials and Methods
Database
The database was collected by Elaine Fehrman between March 2011 and March 2012.
In January 2011, the research proposal was approved by the University of Leicester’s
Forensic Psychology Ethical Advisory Group, and subsequently received favourable
opinion from the University of Leicester School of Psychology’s Research Ethics
Committee (PREC).
The data are available online [27]. An online survey tool from Survey Gizmo was
employed to gather data which maximised anonymity, this being particularly relevant
to canvassing respondents’ views, given the sensitive nature of drug use. All
participants were required to declare themselves at least 18 years of age prior to
informed consent being given.
The study recruited 2051 participants over a 12-month recruitment period. Of
these persons, 166 did not respond correctly to a validity check built into the middle
of the scale, so were presumed to being inattentive to the questions being asked. Nine
of these persons were found to also have endorsed using a fictitious recreational drug,
and which was included precisely to identify respondents who over-claim, as have
other studies of this kind [43]. This led a useable sample of 1885 participants
(male/female = 943/942).
The snowball sampling methodology recruited a primarily (93.7%) native
English-speaking sample, with participants from the UK (1044; 55.4%), the USA (557;
29.5%), Canada (87; 4.6%), Australia (54; 2.9%), New Zealand (5; 0.3%) and Ireland
(20; 1.1%). A total of 118 (6.3%) came from a diversity of other countries, none of
whom individually met 1% of the sample or did not declare the country of location.
Further optimizing anonymity, persons reported their age band, rather than their
exact age; 18-24 years (643; 34.1%), 25-34 years (481; 25.5%), 35-44 years (356; 18.9%),
45-54 years (294; 15.6%), 55-64 (93; 4.9%), and over 65 (18; 1%). This indicates that
although the largest age cohort band were in the 18 to 24 range, some 40% of the
cohort was 35 or above, which is an age range often missed in studies of this kind.
The sample recruited was highly educated, with just under two thirds (59.5%)
educated to, at least, degree or professional certificate level: 14.4% (271) reported
holding a professional certificate or diploma, 25.5% (481) an undergraduate degree,
15% (284) a master’s degree, and 4.7% (89) a doctorate. Approximately 26.8% (506)
of the sample had received some college or university tuition although they did not
hold any certificates; lastly, 13.6% (257) had left school at the age of 18 or younger.
Participants were asked to indicate which racial category was broadly
representative of their cultural background. An overwhelming majority (91.2%; 1720)
reported being white, (1.8%; 33) stated they were Black, and (1.4%; 26) Asian. The
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remainder of the sample (5.6%; 106) described themselves as ‘Other’ or ‘Mixed’
categories. This small number of persons belonging to specific non-white ethnicities
precludes any analyses involving racial categories.
Personality measurements
In order to assess personality traits of the sample, the Revised NEO Five-Factor
Inventory (NEO-FFI-R) questionnaire was employed [11]. The NEO-FFI-R is a highly
reliable measure of basic personality domains; internal consistencies are 0.84 (N); 0.78
(E); 0.78 (O); 0.77 (A), and 0.75 (C) Egan [44]. The scale is a 60-item inventory
comprised of five personality domains or factors. The NEO-FFI-R is a shortened
version of the Revised NEO-Personality Inventory (NEO-PI-R) [11]. The five factors
are: N, E, O, A, and C with 12 items per domain. The five traits can be summarized
as:
1. Neuroticism (N) is a long-term tendency to experience negative emotions such
as nervousness, tension, anxiety and depression;
2. Extraversion (E) is manifested in outgoing, warm, active, assertive, talkative,
cheerful, and in search of stimulation characteristics;
3. Openness to experience (O) is a general appreciation for art, unusual ideas, and
imaginative, creative, unconventional, and wide interests,
4. Agreeableness (A) is a dimension of interpersonal relations, characterized by
altruism, trust, modesty, kindness, compassion and cooperativeness;
5. Conscientiousness (C) is a tendency to be organized and dependable,
strong-willed, persistent, reliable, and efficient.
All of these domains are hierarchically defined by specific facets [45]. Egan et
al [33] observe that the score O and E domains of the NEO-FFI instrument are less
reliable than N, A, and C.
Participants were asked to read the 60 NEO-FFI-R statements and indicate on a
five-point Likert scale how much a given item applied to them (i.e. 0 = ‘Strongly
Disagree’, 1 = ‘Disagree’, 2 = ‘Neutral’, 3 = ‘Agree’, to 4 = ‘Strongly Agree’).
We expected that drug usage is associated with high N, and low A and C. The
darker dimension of personality can be described in terms of high N and low A and C,
whereas much of the anti-social behaviour in non-clinical persons appears underpinned
by high N and low C [46]. The so-called ‘negative urgency’ is the tendency to act
rashly when distressed, and characterized by high N, low C, and low A [47]. The
negative urgency is partially proved below for users of most of the illegal drugs. In
addition, our findings suggest that O is higher for drug users.
The second measure used was the Barratt Impulsiveness Scale (BIS-11) [29]. The
BIS-11 is a 30-item self-report questionnaire, which measures the behavioural
construct of impulsiveness, and comprises three subscales: motor impulsiveness,
attentional impulsiveness, and non-planning. The ‘motor’ aspect reflects acting
without thinking, the ‘attentional’ component poor concentration and thought
intrusions, and the ‘non-planning’ a lack of consideration for consequences [48]. The
scale’s items are scored on a four-point Likert scale. This study modified the response
range to make it compatible with previous related studies [49]. A score of five usually
connotes the most impulsive response although some items are reverse-scored to
prevent response bias. Items are aggregated, and the higher BIS-11 scores, the higher
the impulsivity level [50]. The BIS-11 is regarded a reliable psychometric instrument
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Definitions of users 
Week-based  
Month-based 
` Year-based  
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Used in last day 
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Used in last year 
Used in last decade 
Fig 1. Categories of drug users. Categories with green background always
correspond to drug non-users. Four different definitions of drug users are presented.
with good test-retest reliability (Spearman’s rho is equal to 0.83) and internal
consistency (Cronbach’s alpha is equal to 0.83; [29, 48].
The third measurement tool employed was the Impulsiveness Sensation-Seeking
(ImpSS). Although the ImpSS combines the traits of impulsivity and sensation-seeking,
it is regarded as a measure of a general sensation-seeking trait [30]. The scale consists
of 19 statements in true-false format, comprising eight items measuring impulsivity
(Imp), and 11 items gauging sensation-seeking (SS). The ImpSS is considered a valid
and reliable measure of high risk behavioural correlates such as, substance misuse [51].
Drug use
Participants were questioned concerning their use of 18 legal and illegal drugs (alcohol,
amphetamines, amyl nitrite, benzodiazepines, cannabis, chocolate, cocaine, caffeine,
crack, ecstasy, heroin, ketamine, legal highs, LSD, methadone, magic mushrooms,
nicotine and volatile substance abuse (VSA)) and one fictitious drug (Semeron) which
was introduced to identify over-claimers.
It was recognised at the outset of this study that drug use research regularly (and
spuriously) dichotomises individuals as users or non-users, without due regard to their
frequency or duration/desistance of drug use [52]. In this study, finer distinctions
concerning the measurement of drug use have been deployed, due to the potential for
the existence of qualitative differences amongst individuals with varying usage levels.
In relation to each drug, respondents were asked to indicate if they never used this
drug, used it over a decade ago, or in the last decade, year, month, week, or day. This
format captured the breadth of a drug-using career, and the specific recency of use.
Different categories of drug users are depicted in Fig 1.
Analysis of the classes of drug users shows that part of the classes are nested:
participants which belong to the category ‘Used in last day’ also belong to the
categories ‘Used in last week’, ‘Used in last month’, ‘Used in last year’ and ‘Used in
last decade’. There are two special categories: ‘Never used’ and ‘Used over a decade
ago’ (see Fig 1). Data does not contain a definition of users and non-users groups.
Formally only a participant in the class ‘Never used’ can be called a non-user, but it is
not a seminal definition because a participant who used a drug more than decade ago
cannot be considered a drug user for most applications. There are several possible way
to discriminate participants into groups of users and non-users for binary classification:
1. Two isolated categories (‘Never used’ and ‘Used over a decade ago’) are placed
into the class of non-users with a green background in Fig 1 and all other
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categories into the class ‘users’ as the simplest version of binary classification.
This classification problem is called ‘decade-based ’ user/non-user separation.
2. The categories ‘Used in last decade’, ‘Used over a decade ago’ and ‘Never used’
are merged to form a group of non-users and all other categories are placed into
the group of users. This classification problem is called ‘year-based ’.
3. The categories ‘Used in last year’, ‘Used in last decade’, ‘Used over a decade ago’
and ‘Never used’ are combined to form a group of non-users and all three other
categories are placed into the group of users. This classification problem is called
‘month-based ’.
4. The categories ‘Used in last week’ and ‘Used in last month’ are merged to form a
group of users and all other categories are placed into the group of non-users.
This classification problem is called ‘week-based ’.
We begin our analysis from the decade-based user/non-user separation because it is
a relatively well balanced classification problem, that is, there are sufficiently many
users in the united group ‘Used in last decade-year-month-week’ for all drugs in the
database. If the problem is not directly specified then it is the decade-based
classification problem. We also perform analysis for the year-, month-, and week-based
user/non-user separation. It is useful to group drugs with highly correlated usage for
this purpose (see Section ‘Pleiades of drugs’).
The proportion of drug users among all participants is different for different drugs
and for different classification problems. The data set comprises 1885 individuals
without any missing data. Table 1 shows the percentage of drug users for each drug
and for each problem in the database. It is necessary to mention that the sample is
biased to a higher proportion of drug users. This means that for the general population
the fraction of an illegal drug users is expected to be significantly lower [53].
Table 1. The number and fraction of drug users
Drug User definition based on
Decade Year Month Week
Alcohol 1817; 96.39% 1749; 92.79% 1551; 82.28% 1264; 67.06%
Amphetamines 679; 36.02% 436; 23.13% 238; 12.63% 163; 8.65%
Amyl nitrite 370; 19.63% 133; 7.06% 41; 2.18% 17; 0.90%
Benzodiazepines 769; 40.80% 535; 28.38% 299; 15.86% 179; 9.50%
Cannabis 1265; 67.11% 999; 53.00% 788; 41.80% 648; 34.38%
Chocolate 1850; 98.14% 1840; 97.61% 1786; 94.75% 1490; 79.05%
Cocaine 687; 36.45% 417; 22.12% 159; 8.44% 60; 3.18%
Caffeine 1848; 98.04% 1824; 96.76% 1764; 93.58% 1658; 87.96%
Crack 191; 10.13% 79; 4.19% 20; 1.06% 11; 0.58%
Ecstasy 751; 39.84% 517; 27.43% 240; 12.73% 84; 4.46%
Heroin 212; 11.25% 118; 6.26% 53; 2.81% 29; 1.54%
Ketamine 350; 18.57% 208; 11.03% 79; 4.19% 37; 1.96%
Legal highs 762; 40.42% 564; 29.92% 241; 12.79% 131; 6.95%
LSD 557; 29.55% 380; 20.16% 166; 8.81% 69; 3.66%
Methadone 417; 22.12% 320; 16.98% 171; 9.07% 121; 6.42%
MMushrooms 694; 36.82% 434; 23.02% 159; 8.44% 44; 2.33%
Nicotine 1264; 67.06% 1060; 56.23% 875; 46.42% 767; 40.69%
VSA 230; 12.20% 95; 5.04% 34; 1.80% 21; 1.11%
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Fig 2. Mean T-score NEO-FFI-R
Data analysis
The raw score for each factor of the NEO-FFI-R was converted into a T-Score based
on normative data [28]:
T -score = 10
[
Raw score −Normative mean score
Normative standard deviation
]
+ 50 (1)
Table 2 presents statistics: sample means, sample standard deviation (SD), and
evaluation of the significance of the difference between the sample mean and the
population mean. All differences between the population and sample means are
statistically significant (p < 0.001).
Table 2. Descriptive statistics (Mean, 95% CI, SD). p-value is calculated by t-test.
Factors Sample mean 95% CI for sample mean SD Population mean p-value
N 59.64 59.08, 60.20 12.41 50 <0.001
E 47.35 46.88, 47.83 10.48 50 <0.001
O 54.04 53.55, 54.52 10.75 50 <0.001
A 47.15 46.62, 47.69 11.88 50 <0.001
C 43.93 43.25, 44.61 11.06 50 <0.001
The means of the NEO-FFI-R T-scores based on normative data are depicted in
Fig 2. Table 2 and Fig 2 illustrate that the sample is biased with respect to the
population. Such a bias is usual for clinical cohorts, for example, the ‘problematic’ or
‘pathological’ groups [54] and the drug users [14, 16]. It is highlighted below that the
sample in this study deviates from the population norm in the same direction as drug
users deviate from sample mean (see Table 5). However, the deviances of mean of
users groups are different for different drugs. Therefore, it is convenient to study
deviations of users and non-users from the sample mean. We introduce sample based
T-score for this purpose .
T-scoresample is introduced for improving the visibility and simplicity of a
comparison and is calculated using equation (2). The resulting T-scoresample contains
a mean of 50 and a standard deviation of 10.
T -scoresample = 10
[
Raw score − Sample mean score
Sample standard deviation
]
+ 50 (2)
Usually, the T-score is categorized into five categories to summarise an individual’s
personality score concerning each factor. The interval 20-35 indicates very low scores.
The interval 35-45 indicates low scores. The interval 45-55 indicates average scores.
The interval 55-65 indicates high scores. The interval 65-80 indicates very high scores.
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This study considers the mean T-scoresample for two groups (users and non-users)
instead of each individual’s score. A subdivision of the T-scoresample interval is
introduced as follows: the interval 44-49 indicates moderately low (−), the interval
49-51 indicates neutral (0), and the interval 51-56 indicates moderately high (+).
The unification of the mean and variance of the T-scoresample for all factors
simplifies comparisons of groups (both users and non-users) for each drug. Any
differences between the mean T-scoresample for groups of users and non-users is
usually used as a measure of the groups’ dissimilarity in scores. The NEO-FFI-R
scores for groups of users and non-users for each drug were represented by the mean
T-scoresample of these groups for each factor. A t-test is employed to estimate the
significance of the differences between the mean T-scoresample for groups of users and
non-users for each NEO-FFI-R factor and each drug. In this t-test, a p-value is a
probability of observing by chance the same or a greater difference of mean for two
samples with the same mean. The 90% level is chosen to select significant differences.
The analysis was performed using SAS 9.4.
Input feature transformation
There are many data mining methods to work with continuous data. It is necessary to
quantify all categorical features to use these methods especially for features with many
levels. To apply logistic regression to these data with categorical features and
corresponding coefficients, we have to use dummy coding directly or indirectly. In this
case we have n− 1 coefficients for a feature with n levels, meaning that we fit logistic
regression in a 250 dimensional space (age contains six levels, gender contains two
levels, education contains nine levels, country contains seven levels, ethnicity contains
seven levels, N score contains 49 levels, E score contains 42 levels, O score contains 35
levels, A score contains 41 levels, C score contains 41 levels, impulsivity contains 10
levels, and SS contains 11 levels: 5 + 1 + 8 + 6 + 6 + 48 + 41 + 34 + 41 + 41 + 9 +
10 = 250). After quantification we can fit a logistic regression model in a 12
dimensional space. This means that feature quantification can be used as an effective
dimensionality reduction method.
Ordinal feature quantification
One of the widely used techniques to analyse categorical data is the calculation of
polychoric correlation [55, 56]. The matrix of polychoric coefficients is used further to
calculate principal components (PCs), etc. The technique of polychoric correlation is
based on the assumption that values of ordinal features result from the discretization
of continuous random values with fixed thresholds. Furthermore, these latent
continuous random values follow a normal distribution. Unfortunately, the polychoric
correlation technique has two drawbacks: it defines the thresholds of discretization but
not the values for each category, and the defined thresholds differ for different pairs of
attributes.
Consider the ordinal feature o with categories o1,o2,...,ok and with number of cases
ni of category oi. The empirical estimation of the probability of category oi is
pi = ni/N , where N =
∑
ni. The sample estimation of thresholds are evaluating as:
ti = φ
−1
(
i∑
j=1
pj
)
(3)
The simplest method of the ordinal feature quantification is to use the
thresholds (3) and select the ‘average’ value in each interval. There are several
variants of the ‘average’ value. In this study we use the value with average probability:
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if thresholds ti−1 and ti define the interval of category oi, then average probability for
this interval is
qi = φ
−1
(
i−1∑
j=1
pj +
pi
2
)
(4)
The polychoric coefficients, calculated on base of quantification (4), have less
likelihood than the polychoric coefficients calculated by using the maximum likelihood
approach. The merit of this approach is the usage of the same thresholds for all pairs
of attributes and explicit formulae for calculating the categories’ values.
Nominal feature quantification
We cannot use the techniques described above to quantify nominal features such as
gender, country of location and ethnicity because the categories of these features are
unordered. To quantify nominal features we implemented the technique of nonlinear
CatPCA (Categorical Principal Component Analysis) [57]. This procedure includes
four steps:
1. Exclude nominal features from the set of input features and calculate the
informative PCs [58–61] in the space of retained input features. To select
informative components we use Kaiser’s rule [62, 63].
2. Calculate the centroid of each category in projection on selected PCs.
3. Calculate the first PC of centroids.
4. The numerical value for each component is the projection of its centroid on this
component.
Algorithm 1 Nominal feature quantification
1: Exclude nominal features from the set of input features and calculate the infor-
mative PCs [58–61] in the space of retained input features. To select informative
components we use Kaiser’s rule [62, 63].
2: Calculate the centroid of each category in projection on selected PCs.
3: Calculate the first PC of centroids.
4: The numerical value for each category is the projection of its centroid on this com-
ponent.
The process of nominal feature quantification for the feature ‘country’ is depicted
in Fig 3. Fig 3 shows that points corresponding to the UK category are located very
far from any other points.
As an alternative variant of nominal feature quantification we use dummy
coding [64] of nominal variables: ‘country’ is transformed into seven binary features
with values 1 (if ‘true’) or 0 (if ‘false’): UK, Canada, USA, Other (country), Australia,
Republic of Ireland and New Zealand; Ethnicity is transformed into seven binary
features: Mixed-White/Asian, White, Other (ethnicity), Mixed-White/Black, Asian,
Black and Mixed-Black/Asian.
Input feature ranking
In this study, we used three different techniques for input feature ranking. The first
technique was principal variables [65]. Principal variables are a set of input features
which explain the maximal fraction of the data variance. The main idea of this
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Fig 3. Nominal feature quantification of ‘Country’
approach is to select first the input feature which explains the maximal fraction of the
data variance, then select the next feature which together with the previously selected
features explains the maximal fraction of data variance, and so on.
The second technique was double Kaiser’s selection. Calculate PCs and select
informative PCs by Kaiser’s rule [62, 63]. Kaiser’s rule states the all PCs which
correspond to eigenvalues greater than the average are informative and all other PCs
are uninformative. We apply the covariance based PCs. that is, we calculate PCs as
the normalized eigenvectors of the covariance matrix. For them, the Kaiser rule
threshold is equal to the trace of the covariance matrix divided by the number of
attributes. The importance of an attribute is defined as the maximum of the absolute
value of the corresponding coordinates in the informative PCs. In attribute selection
we define the threshold of importance as the average value of coordinate which is equal
to 1/
√
n for a unit length vector, where n is the number of attributes. If the attribute
importance is greater than the threshold of importance then this attribute is
informative. Otherwise, the attribute is trivial. If there are trivial attributes then the
worst attribute is the attribute with minimal value of importance. We removed the
worst attribute and repeated the procedure. This procedure stops if there are no
trivial attributes. This algorithm ranks attributes from worst to best.
The third technique was sparse PCA [66]. In this study, we used the simplest
thresholding sparse PCA. The searching for each sparse PC contains several steps:
1. Define the number of features n, variance of data σ2, the Kaiser threshold for
the components h = σ2/n and the Kaiser threshold for the coefficients c = 1/
√
n.
2. Search for the usual PC and calculate the variance σ2c explained by this
component. The iterative algorithm gives the PCs in descending order of σ2c .
3. If σ2c < h then all the informative components are found. Remove the last
component and go to step 8.
4. Search the attribute with non-zero coefficients with least absolute value cmin.
5. If cmin > c then there are no trivial attributes found. Go to step 7.
6. Set the value of the found coefficient to zero. Block changes to this attribute
coefficient and search the PC under this condition. Go to step 4.
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7. Subtract the projection onto the found component from the data and go to step
2.
8. Search the attributes with zero coefficients in each found component. These
attributes are trivial. If there are trivial attributes then remove them from the
set of attributes and go to step 1, else stop.
Algorithm 2 Search of sparse PC
1: Define the number of features n, variance of data σ2, the Kaiser threshold for the
components h = σ2/n and the Kaiser threshold for the coefficients c = 1/
√
n.
2: Search for the usual PC and calculate the variance σ2c explained by this component.
The iterative algorithm gives the PCs in descending order of σ2c .
3: if σ2c < h then
4: All the informative components are found. Remove the last component and go
to step 10.
5: Search the attribute with non-zero coefficients with least absolute value cmin.
6: if cmin > c then
7: There are no trivial attributes found. Go to step 9.
8: Set the value of the found coefficient to zero. Block changes to this attribute coeffi-
cient and search the PC under this condition. Go to step 5.
9: Subtract the projection onto the found component from the data and go to step 2.
10: Search the attributes with zero coefficients in each found component. These at-
tributes are trivial.
11: if there are trivial attributes then
12: Remove trivial attributes from the set of attributes and go to step 1.
13: else
14: Stop
Risk evaluation methods
In this study, we applied several classification methods which provide risk evaluation.
We used the set of input features after quantification described in the ‘Ordinal feature
quantification’ Section and in the ‘Nominal feature quantification’ Section. It includes
age, gender, education, N, E, O, A, C, Imp., and SS.
k Nearest Neighbours (kNN)
The basic concept of kNN is the class of an object is the class of the majority of its k
nearest neighbours [67]. This algorithm is very sensitive to distance definition. There
are several commonly used variants of distance for kNN: Euclidean distance;
Minkovsky distance; and distances calculated after some transformation of the input
space.
In this study, we used three distances: the Euclidean distance, the Fisher’s
transformed distance [68] and the adaptive distance [69]. Moreover, we used a
weighted voting procedure with weighting of neighbours by one of the standard kernel
functions [70].
The kNN algorithm is well known [67]. The adaptive distance transformation
algorithm is described in [69]. kNN with Fisher’s transformed distance is less known.
The following parameters are used: k is the number of nearest neighbours, K is the
kernel function, and kf is the number of neighbours which are used for the distance
15
transformation. To define the risk of drug consumption we have to do the following
steps:
1. Find the kf nearest neighbours of the test point.
2. Calculate the covariance matrix of kf neighbours and Fisher’s discriminant
direction.
3. Find the k nearest neighbours of the test point using the distance along Fisher’s
discriminant direction among the kf neighbours found earlier.
4. Define the maximal distance from the test point to k neighbours.
5. Calculate the membership for each class as a sum of the points’ weights. The
weight of a point is the ratio: the value of the kernel function K of distance from
this point to the test point divided by the maximal distance defined at step 4.
6. Drug consumption risk is defined as the ratio of the positive class membership to
the sum of memberships of all classes.
Algorithm 3 kNN with Fisher’s transformed distance
1: Find the kf nearest neighbours of the test point.
2: Calculate the covariance matrix of kf neighbours and Fisher’s discriminant direc-
tion.
3: Find the k nearest neighbours of the test point using the distance along Fisher’s
discriminant direction among the kf neighbours found earlier.
4: Define the maximal distance from the test point to k neighbours.
5: Calculate the membership for each class as a sum of the points’ weights. The weight
of a point is the ratio: the value of the kernel function K of distance from this point
to the test point divided by the maximal distance defined at step 4.
6: Drug consumption risk is defined as the ratio of the positive class membership to
the sum of memberships of all classes.
The adaptive distance version implements the same algorithm but uses another
transformation on step 2 and another distance on step 3 [69]. The Euclidean distance
version simply defines kf = k and omits steps 2 and 3 of algorithm. We tested 1,683
million versions of the kNN models per drug, which differ by:
• The number of nearest neighbours, which varies between 1 and 30;
• The set of input features;
• One of the three distances: Euclidean distance, adaptive distance and Fisher’s
distance;
• The kernel function for adaptive distance transformation;
• The kernel functions for voting.
• Weight of class ‘users’ is varied between 0.01 and 5.0.
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Decision Tree (DT)
The decision tree approach is a classifier that constructs a tree like structure, which
can be used to choose between several courses of action. Binary decision trees are used
in this study. A decision tree is comprised of nodes and leaves. Each node can have a
child node. If a node has no child node, it is called a leaf or a terminal node. Any
decision tree contains one root node, which has no parent node. Each non terminal
node calculates its own Boolean expression (with the value ‘true’ or ‘false’). According
to the result of this calculation, the decision for a given sample would be delegated to
the left child node (’true’) or to the right child node (’false’). Each leaf (terminal
node) has a label which shows how many samples of the training set belong to each
class. The probability of each class is estimated as a ratio of the number of samples in
this class to the total number of samples in the leaf.
There are many methods for developing a decision tree [71–77]. We use the
methods based on information gain, Gini gain, and DKM gain. Let us consider one
node and one binary input attribute which can take values 0 or 1. Let us use notation:
N is the number of cases in the node, c is the number of categories of the target
feature, nij is the number of i category cases with input attribute value j in the node,
the number of i category cases in the node is ni. = ni0 + ni1the number of cases with
the input attribute value j in the node is n.j =
∑c
i=1 nij , where nj =
(
n1j , ..., ncj
)
is
the vector of frequencies with input attribute value j, and n =
(
n1., ..., nc.
)
is the
vector of frequencies with any input attribute value. To form a tree we select the base
function for information criterion among
Entropy
(
m, M
)
= −
c∑
i=1
mi
M
log2
mi
M
,
Gini
(
m, M
)
= 1−
c∑
i=1
(
mi
M
)2
,
and
DKM
(
m,M
)
= 2
√
m0m1M−2,
where m is the vector of frequencies and M is the sum of the elements of the vector m.
The DKM can be applied to a binary target feature only. The value of the criterion is
the gain of base function:
BG = Base(n,N)− n0
N
Base(n.0, n0)− n1
N
Base(n.1, n1).
There are several approaches to use real valued inputs in decision trees. A
commonly used approach is the binning of real valued attributes before forming the
tree. In this study we implemented ‘on the fly’ binning: the best threshold is searched
in each node for each real valued attribute and then this threshold is used to bin these
feature in this node. The best threshold depends on the split criteria used
(information gain, Gini gain, or DKM gain).
Another possibility we employ is the use of Fisher’s discriminant to define the best
linear combination of the real valued features [68] in each node. Pruning techniques
are applied to improve the tree.
The specified minimal number of instances in the tree’s leaf is used as a criterion to
stop node splitting. Each leaf of the tree cannot contain fewer than a specified number
of instances.
We tested 166 million decision tree models (per drug), which differ by:
• The three split criterion (information gain, Gini gain or DKM gain);
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• The use of the real-valued features in the splitting criteria separately or in linear
combination by Fisher’s discriminant;
• The set of input features;
• The minimal number of instances in the leaf, which varied between 3 and 30.
• Weight of class ‘users’ is varied between 0.01 and 5.0.
Linear Discriminant Analysis (LDA)
We used Fisher’s linear discriminant for the binary version of the problem [68], to
separate users from non-users of each drug. We calculate the mean of points of the ith
class, µi, and covariance matrix of the ith class Σi for both classes (i = 1, 2). Then we
calculate the discriminating direction as
ω =
(
Σ1 +Σ2
)
−1(
µ1 − µ2
)
.
Each point is projected onto the discriminating direction by calculating the dot
product (ω, xi). The threshold to separate two classes is calculated by finding the
maximum of relative information gain, Gini gain, or DKM gain. This method cannot
be used for problems of risk evaluation.
In the study we tested 8,192 LDA models per drug, which differ by one of the three
criteria (information gain, Gini gain or DKM gain) which were used to define the
threshold and the set of input features.
Gaussian Mixture (GM)
Gaussian mixture is a method of estimating probability under the assumption that
each category of a target feature has a multivariate normal distribution [78]. In each
category we should estimate the covariance matrix and invert it. The primary
probability of belonging to the ith category is:
pi(x) = p
0
i (2pi)
−
k
2 |Σi|− 12 e− 12 (x− µi)′Σ−1i (x− µi)
where p0i is a prior probability of the ith category, k is the dimension of the input
space, µi is the mean point of the ith category, x is the tested point, Σi is the
covariance matrix of the ith category and |Σi| is its determinant. The final probability
of belonging to the ith category is calculated as
pfi (x) = pi(x)/
∑
j
pj(x).
The prior probabilities are estimated as the proportion of cases in the ith category.
We also used s varied multiplier to correct priors for the binary problem.
In the study, we tested 1,024 million Gaussian mixture models per drug, which
differ by the set of input features and corrections applied to the prior probabilities.
Probability Density Function Estimation (PDFE)
We implemented the radial-basis function method [79] for probability density function
estimation [80]. The number of probability densities to estimate is equal to the
number of categories of the target feature. Each probability density function is
estimated separately by using nonparametric techniques. The prior probabilities are
estimated from the database: pi = ni/N where ni is the number of cases with i
category of the target feature and N is the total number of cases in the database.
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We also use the database to define the k nearest neighbours of each data point.
These k points are used to estimate the radius of the neighbourhood of each point as a
maximum of the distance from the data point to each of its k nearest neighbours. The
centre of one of the kernel functions is placed at the data point [70]. The integral of
any kernel function over the whole space is equal to one. The total probability of the
ith category is proportional to the integral of the sum of the kernel functions, which is
equal to ni. The total probability of each category has to be equal to the prior
probability pi. Thus, the sum of the kernel functions has to be divided by ni and
multiplied by pi. This gives the probability density estimation for each category.
We tested 426,000 versions of the PDFE models per drug, which differ by:
• The number of nearest neighbours (varied between 5 and 30);
• The set of the input features;
• The kernel function which was placed at each data points.
Logistic Regression (LR)
We implemented the weighted version of logistic regression [81]. This method can be
used for binary problem only. The log likelihood estimate of the regression coefficients
is used. The weights of categories are defined as the fraction of the ith category cases
among all cases. Logistic regression gives only one result because there is no option to
customize the method except by the set of input features. In our study we tested 2,048
LR models per drug.
Na¨ıve Bayes (NB)
We implemented the standard version of na¨ıve Bayes [82]. All attributes which
contained ≤20 different values were interpreted as categorical and the standard
contingency tables were calculated for such attributes. Calculated contingency tables
are used to estimate the conditional probabilities. Attributes which contain more than
20 different values were interpreted as continuous. The mean and the variance were
calculated for continuous attributes instead of the contingency tables. We calculated
the isolated mean and variance for each value of the output attribute. The conditional
probability of a specified outcome o and a specified value of the attribute x were
calculated as the value of the probability density function for a normal distribution at
point x with matched mean and variance, which were calculated for the outcome o.
This method has no customization options and was tested on different sets of input
features. In the study we tested 2,048 NB models per drug.
Random Forest (RF)
Random forests were proposed by Breiman [83] for building a predictor ensemble with
a set of decision trees that grow in randomly selected subspaces of the data [84]. The
random forests classification procedure consists of a collection of tree structured
classifiers h
(
x,Θk), k = 1, ..., where the Θk are independent identically distributed
random vectors and each tree casts a unit vote for the most popular class at input
x” [83].
In a random forest, each tree is constructed using a different bootstrap sample
from the original data [85]. In standard trees, each node is split using the best split
among all variables. In a random forest, each node is split using the best among a
subset of predictors randomly chosen at that node [86].
Random forests try to improve on bagging by ‘de-correlating’ the trees. Each tree
has the same expectation [85]. The forest error rate depends on two things [83]. The
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first is the correlation between any two trees in the forest. Increasing the correlation
increases the forest error rate. The second is the strength of each individual tree in the
forest. A tree with a low error rate is a strong classifier. Increasing the strength of the
individual trees decreases the forest error rate. The random forest algorithm builds
hundreds of decision trees and combines them into a single model [87]. In the case
study we tested 2,048 RF models per drug.
Criterion for selecting the best method
A number of different criteria exist for the selection of the best classifier. The criterion
we used was to pick the method such that the minimum vetween sensitivity and
specificity was maximised. If minimum between sensitivity and specificity is the same
for two classifiers, then we select the classifier with the maximal sum of the sensitivity
and specificity. Classifiers with sensitivity or specificity less than 50% were not
considered. There are several approaches to test the quality of classifier: usage of
isolated test set, n-fold cross validation and Leave-One-Out Cross Validation(
LOOCV
)
[88]. LOOCV is used for all tests in this study. There are some problems
with classifier quality estimation for the technique like decision tree and random forest.
These problems are considered in details by Hastie et al [85].
Results
The data set contains seven categories of drug uses: ‘Never used’, ‘Used over a decade
ago’, ‘Used in last decade’, ‘Used in last year’, ‘Used in last month’, and ‘Used in last
week’. We form four problems based on four dichotomies of these classes (see ‘Drug
use’ Section): the decade-, year-, month-, and week-based user/non-user separations.
We identified the relationship between personality profiles (NEO-FFI-R) and drug
consumption for the decade-, year-, month-, and week-based classification problems.
We evaluated the risk of drug consumption for each individual according to their
personality profiles. This evaluation was performed separately for each drug for the
decade-based user/non-user separation. We also analysed interrelations between the
individual drug consumption risks for different drugs. Part of the results was
presented in the preprint [32]. In addition, in the ‘Pleiades of drugs’ Section we focus
on use of correlation pleiades of drugs. We define three pleiades: heroin pleiade,
ecstasy pleiade, and benzodiazepines pleiade with respect to the decade-, year-,
month-, and week-based user/non-user separations.
Descriptive statistics
The descriptive statistics for five factors are presented in Table 3: means, standard
deviations, normative data (means and standard deviations for the population
following McCrae & Costa (2004) [28]), 95% confidence intervals, kurtosis (kurtosis is
a measure of flatness/‘peakedness’ of the distribution shape compared to normal
distribution) and ‘skewness’ (skewness is a measure of asymmetry of the distribution)
for NEO-FFI-R for the full sample).
Pearson’s correlation coefficient (PCC or r) is employed as a measure of the
strength of a linear association between two factors. PCC for all pairs of factors are
presented in Table 4. Two pairs of factors do not have significant correlation: (1) N
and O (r=0.017, p=0.471); (2) A and O (r=0.033, p=0.155). However, all other pairs
of personality factors are significantly correlated in the sample.
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Table 3. Descriptive statistics (Means, sample Standard Deviations (SD), 95% Confidence Intervals (CI), normative mean
and SD, kurtosis, skewness) for NEO-FFI-R for raw data
Factors Mean 95% CI for mean SD Normative mean Normative SD Kurtosis Skewness
N 23.92 23.51, 24.33 9.14 16.83 7.36 -0.55 0.11
E 27.58 27.27, 27.88 6.77 29.29 6.46 0.06 -0.27
O 33.76 33.47, 34.05 6.58 31.29 6.12 -0.27 -0.30
A 30.87 30.58, 31.16 6.44 32.41 5.42 0.13 -0.26
C 29.44 29.12, 29.75 6.97 33.26 6.3 -0.17 -0.38
Table 4. PCC for NEO-FFI-R for raw data
Factors N E O A C
N -0.432** 0.017 -0.215** -0.398**
E -0.432** 0.236** 0.159** 0.318**
O 0.017 0.236** 0.033 -0.060*
A -0.215** 0.159** 0.033 0.249**
C -0.398** 0.318** -0.060* 0.249**
p-value is the probability to observe by chance the same or greater correlation coefficient if data are uncorrelated: ∗p <0.01;
**p <0.001.
Distribution of number of used drugs
The diagrams in Fig 4 show the graph of the number of users versus the number of
used illegal drugs for the decade-based (A) and month-based (B) user/non-user
separations. In Fig 4A we can see that the distribution of the number of users is
bimodal with maxima in zero and 7 drugs. In Fig 4B distribution of number of regular
users of illegal drugs looks like the exponential distribution.
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Fig 4. The histograms of the number of users: A for the decade-based
user/non-user separation), B for the month-based user/non-user separation
The distributions of the number of users for each drug are presented in Fig 5 and
Fig 6. Most of distributions have the exponential like shape but several have bimodal
distributions. The distributions of the number of users for the three legal drugs have
maximum at ‘Used in last day’ or ‘Used in last week’ (see Fig 5A, E, and G). The
distribution of the number of nicotine users (smokers) has three maxima: ‘Used in last
day’ for smokers, ‘Used in last decade’ for smokers which broken smoking, and ‘Never
used’ (see Fig 6G). All illegal drug users distribution have maximum in the category
‘Never used’. However, distribution of cannabis users has two maxima: the main in the
category ‘Used in last day’ and the second in the category ‘Never used’ (see Fig 5F).
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Fig 5. Distribution of drug usage: A: Alcohol, B: Amphetamines, C: Amyl
nitrite, D: Benzodiazepines, E: Cannabis, F: Chocolate, G: Cocaine, H: Caffeine, I:
Crack, and J: Ecstasy
Comparison of personality traits means for drug users and
non-users
Tables 22, 23, 24, and 25 demonstrate the mean T-scoresample NEO-FFI-R factors for
users and non-users for each drug with respect to the decade-, year-, month-, and
week-based classification problems respectively (see S1 Appendix). Significant
differences in personality factor scores are observed between these groups. The
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Fig 6. Distribution of drug usage: A: Heroin, B: Ketamine, C: Legal highs, D:
LSD, E: Methadone, F: Magic mushrooms, G: Nicotine, and H: VSA
universal relationship between personality profile and risk of drug consumption can
generally be described as follows: an increase in scores of N and O entails an increase
in the risk of use, whereas an increase in the scores of A and C entails a decrease in
risk of use. Thus for each drug, drug users scored higher on N and O, and lower on A
and C when compared to drug non-users. The influence of the score of E is drug
specific (non-universal).
The introduction of moderate subcategories of T-scoresample enables to separates
the drugs into five groups for the decade-based user/non-user separation as presented
in Table 5. Each group can be coded by five moderate subcategories with the
moderate profile (N, E, O, A, C). Firstly, the group with the profile (0, 0, 0, 0, 0)
includes the users of the legal drugs alcohol, chocolate and caffeine. Thus, the
T-scoresample for all factors for legal drug consumers does not significantly differ from
the sample mean. Secondly, the group of drugs with the profile (0, 0,+,−,−) includes
the users of amyl nitrite, LSD, and magic mushrooms. Thirdly, nicotine users form
their own group with the profile (0, 0,+, 0,−). Fourthly, the largest group of drugs
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with the profile (+, 0,+,−,−) includes the users of amphetamines, benzodiazepines,
cannabis, cocaine, ecstasy, ketamine and legal highs. Finally, the group with the
profile (+,−,+,−,−) includes the users of crack, heroin, VSA and methadone.
Table 5. Moderate subcategories of T-scoresample with respect to the sample mean for groups of users for the
decade-based user/non-user separation: (0) indicates a neutral score, (+) indicates moderately high score, and (−) indicates
to moderately low score
Drug N E O A C
Alcohol, Chocolate, Caffeine 0 0 0 0 0
Amyl nitrite, LSD, and Magic Mushrooms 0 0 + − −
Nicotine 0 0 + 0 −
Amphetamines, Benzodiazepines, Cannabis,
Cocaine, Ecstasy, Ketamine, and Legal highs + 0 + − −
Crack, Heroin, VSA, and Methadone + − + − −
All drugs for the year-based user/non-user classification are separated into eight
groups as presented in Table 6. Each group can be coded by five moderate
subcategories with the moderate profile.
1. The group with the profile (0, 0, 0, 0, 0) includes the users of the legal drugs
alcohol, chocolate and caffeine. Thus, T-scoresample for all factors for these legal
drug consumers does not significantly differ from the sample mean.
2. The group of drugs with the profile (0, 0,+,−,−) includes the users of magic
mushrooms.
3. The LSD users form their own group with the profile (0, 0,+, 0,−).
4. The group with the profile (+, 0,+,−,−) includes the users of amphetamines,
amyl nitrite, cannabis, cocaine, crack, legal highs and VSA.
5. The group of drugs with the profile (+,−,+,−,−) includes the users of
benzodiazepines, heroin, and methadone.
6. The ecstasy users form their own group with the profile (0,+,+,−,−).
7. The ketamine users form their own group with the profile (+,+,+,−,−).
8. The nicotine users form their own group with the profile (+, 0,+, 0,−).
Similarly, all drugs for the month-based user/non-user classification are separated
into nine groups (Table 7), and into 10 groups for the week-based user/non-user
classification (Table 8).
The personality profiles are strongly associated with belonging to groups of the
users and non-users of the 18 drugs. We found that the N and O score of drug users of
all 18 drugs are moderately high (+) or neutral (0), and the A and C scores of drug
users are moderately low (−) or neutral (0). Detailed results can be seen in Tables 5,
6, 7, and 8.
The effect of the E score is drug specific. All drugs are divided in three groups with
respect to the E score of users (in the year-, month-, and week-based classification
problems) (see Tables 5, 6, 7 and 8). For example, for the week-based user/non-user
separation the E score is:
• Moderately low (−) in groups of users of amphetamines, amyl nitrite,
benzodiazepines, heroin, ketamine, legal highs, methadone, and crack;
24
Table 6. Moderate subcategories of T-scoresample with respect to the sample mean for groups of users for the year-based
user/non-user separation: (0) indicates a neutral score, (+) indicates moderately high score, and (−) indicates moderately
low score
Drug N E O A C
Alcohol, Chocolate, Caffeine 0 0 0 0 0
Magic Mushrooms 0 0 + − −
LSD 0 0 + 0 −
Amphetamines, Amyl nitrite, Cannabis,
Cocaine, Crack, Legal highs, and VSA + 0 + − −
Benzodiazepines, Heroin, and Methadone + − + − −
Ecstasy 0 + + − −
Ketamine + + + − −
Nicotine + 0 + 0 −
Table 7. Moderate subcategories of T-scoresample with respect to the sample mean for groups of users for the
month-based user/non-user separation: (0) indicates a neutral score, (+) indicates moderately high score, and (−) indicates
moderately low score
Drug N E O A C
Alcohol, Chocolate, Caffeine 0 0 0 0 0
Cannabis and Magic Mushrooms 0 0 + − −
Nicotine + 0 + 0 −
Amphetamines, Ketamine, and Legal highs + 0 + − −
Benzodiazepines, Heroin, and Methadone + − + − −
Ecstasy and LSD 0 + + − −
Cocaine and VSA + + + − −
Amyl nitrite 0 0 0 − −
Crack + − 0 − −
Table 8. Moderate subcategories of T-scoresample with respect to the sample mean for groups of users for the week-based
user/non-user separation: (0) indicates a neutral score, (+) indicates moderately high score and (−) indicates moderately
low score
Drug N E O A C
Alcohol, Chocolate, Caffeine 0 0 0 0 0
Cannabis 0 0 + − −
LSD and Magic Mushrooms 0 + + 0 −
Ketamine 0 − + − −
Amphetamines, Benzodiazepines, Heroin, Legal highs, and Methadone + − + − −
Ecstasy and VSA 0 + + − −
Cocaine + + + − −
Nicotine + 0 + 0 −
Amyl nitrite 0 − 0 − −
Crack + − − − −
• Moderately high (+) in groups of users of cocaine, ecstasy, LSD, magic
mushrooms, and VSA;
• Neutral (0) in groups of users of alcohol, caffeine, chocolate, cannabis, and
nicotine.
Tables 9, 10, 11, and 12 represent significant differences between the means of the
personality traits for the group of users and the group of non-users for the decade-,
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year-, month-, and week-based classification problems. A 99% significance level is used
(p-value is less than 0.01).
For example, three out of the six groups for the decade-based user/non-user
separation correspond to legal drugs (see Table 9). Chocolate does not have significant
difference between users and non-users for all factors. Alcohol users and non-users
have a significant difference only in the C score, and caffeine users and non-users have
a significant difference only in the O score. Amyl nitrite, LSD, and magic mushrooms
form a group with significant differences between users and non-users for three factors:
O, A, and C. The next group contains amphetamines, cannabis, cocaine, crack,
ecstasy, heroin, ketamine, legal highs, nicotine, and VSA and have significant
differences between users and non-users for four factors: N, O, A, and C. The last
group consists of two drugs: benzodiazepines and methadone. Groups of users differ
significantly from groups of non-users for these drugs in values of all factors.
Table 9. Significant differences of means for groups of users and non-users for the decade-based user/non-user separation.
Symbol ‘ ⇓ ’ corresponds to significant difference where the mean in users group is less than mean in non-users group and
symbol ‘⇑ corresponds to significant difference where the mean in users group is greater than the mean in non-users group.
Empty cells corresponds to insignificant differences. Difference is considered as significant if p-value is less than 0.01).
Drug N E O A C
Chocolate
Alcohol ⇓
Caffeine ⇑
Amyl nitrite, LSD, and Magic Mushrooms ⇑ ⇓ ⇓
Amphetamines, Cannabis, Cocaine, Crack, Nicotine,
Ecstasy, Heroin, Ketamine, Legal highs, and VSA ⇑ ⇑ ⇓ ⇓
Benzodiazepines and Methadone ⇑ ⇓ ⇑ ⇓ ⇓
Table 10. Significant differences of means for groups of users and non-users for the year-based user/non-user separation.
Symbol ‘ ⇓ ’ corresponds to significant difference where the mean of users group is less than the mean of non-users group
and symbol ‘⇑ corresponds to significant difference where the mean of users group is greater than the mean of non-users
group. Empty cells corresponds to insignificant differences. Difference is considered as significant if p-value is less than 0.01.
Drug N E O A C
Chocolate, Alcohol, Caffeine
Amyl nitrite ⇓ ⇓
LSD ⇑ ⇓
Ketamine and Magic Mushrooms ⇑ ⇓ ⇓
VSA ⇑ ⇑ ⇓
Amphetamines, Cannabis, Cocaine,
Crack, Nicotine,Heroin, and Legal highs ⇑ ⇑ ⇓ ⇓
Ecstasy ⇑ ⇑ ⇓ ⇓
Benzodiazepines and Methadone ⇑ ⇓ ⇑ ⇓ ⇓
Three illicit drugs, amyl nitrite, crack, and cannabis, do not have significant
differences between users and non-users for all factors for the month-based
user/non-user classification problem. VSA users and non-users have significant
difference only for O for this problem. Alcohol and cocaine users have significant
difference from non-users for E only. The group of ketamine, LSD, and magic
mushrooms users have significant differences from non-users for C and O. Heroin users
have significant difference from non-users for C, A, and N factors. The next group
contains amphetamines, caffeine, chocolate, legal highs, and nicotine: their user differ
significantly from non-users for all factors except E.
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The significance of the differences of the means for groups of users and non-users
for the week-based user definition separates the drugs into 10 groups (see Table 12).
Table 11. Significant differences of means for groups of users and non-users for the month-based user/non-user separation.
Symbol ‘ ⇓ ’ corresponds to significant difference where the mean of users group is less than the mean of non-users group
and symbol ‘⇑ corresponds to significant difference where the mean of users group is greater than the mean of non-users
group. Empty cells corresponds to insignificant differences. Difference is considered as significant if p-value is less than 0.01.
Drug N E O A C
Amyl nitrite, Crack, and Cannabis
VSA ⇑
Alcohol and Cocaine ⇑
Ketamine, LSD, and Magic Mushrooms ⇑ ⇓
Heroin ⇑ ⇓ ⇓
Amphetamines, Caffeine, Chocolate,
Legal highs, and Nicotine ⇑ ⇑ ⇓ ⇓
Ecstasy ⇑ ⇑ ⇓ ⇓
Benzodiazepines and Methadone ⇑ ⇓ ⇑ ⇓ ⇓
Table 12. Significant differences of means for groups of users and non-users for the week-based user/non-user separation.
Symbol ‘ ⇓ ’ corresponds to significant difference where the mean of users group is less than the mean of non-users group
and symbol ‘⇑ corresponds to significant difference where the mean of users group is greater than the mean of non-users
group. Empty cells corresponds to insignificant differences. Difference is considered as significant if p-value is less than 0.01.
Drug N E O A C
Amyl nitrite, Caffeine, Crack, Chocolate and Ketamine
Alcohol ⇑
Cocaine ⇓ ⇓
Magic Mushrooms and VSA ⇑
Ecstasy and LSD ⇑ ⇓
Cannabis ⇑ ⇓ ⇓
Heroin ⇑ ⇓ ⇓
Methadone ⇑ ⇓ ⇓ ⇓
Amphetamines and Nicotine ⇑ ⇑ ⇓ ⇓
Benzodiazepines and Legal highs ⇑ ⇓ ⇑ ⇓ ⇓
Mean values of factor scores for groups of drug users and non-users for the
decade-based user/non-user separation are presented in Table 22 and are depicted in
Fig 7. A single drug was chosen to be plotted for each group, due to the fact that the
shapes of the profile for all drugs in one group are very similar. Nicotine is not plotted,
since the factor scores of nicotine users are similar to those of the group consisting of
amyl nitrite, LSD and magic mushrooms. Fig 7 represents T-score graphs of the mean
of personality factor scores for the groups of users and non-users with respect to the
population norm mean (the left column) and with respect to the sample mean (the
right column) for alcohol, LSD, cannabis, and heroin. Graphs of the same type are
presented for the year-based classification problem for ketamine in Fig 8, for amyl
nitrite for the month-based classification problem in Fig 9 and for crack for the
week-based classification problem in Fig 10. Mean values of factor scores for groups of
drug users and non-users for the year-, month- and week-based user/non-user
separations are presented in Tables 23, 24 and 25.
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Fig 7. Average personality profiles for the decade-based user/non-user
separation. T-scores with respect to the population norm mean (left column) and
T-scoresample with respect to the sample means (right column) for: A & B: Alcohol, C
& D: LSD, E & F: Cannabis, and G & H: Heroin
Correlation between usage of different drugs
Usage of each drug is a binary variable (users or non-users) for all versions of user
definition. Tables 26 and 27 contain PCCs, which are computed for each pair of the
drug usages for the decade- and year-based user/non-user separations respectively (see
S2 Appendix). The majority of the PCCs are significant, due to the fact that the
sample size is 1885.
The correlation in 124 pairs of drug usages from a totality of 153 pairs have for the
decade-based classification problem have p-values less than 0.01 (p-value is the
probability to observe by chance the same or greater correlation coefficient for
uncorrelated variables). It is necessary to employ a multi-testing approach when
28
AT
-s
co
re
35
40
45
50
55
60
65
N E O A C B
T
-s
co
re
sa
m
p
le
35
40
45
50
55
60
65
N E O A C
Ketamine
Population mean Sample mean User Non-user Sample mean User Non-user
Fig 8. Average personality profiles for Ketamine for the year-based
user/non-user separation. A: T-scores with respect to the population norm mean
and B: T-scoresample with respect to the sample means
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Fig 9. Average personality profiles for Amyl nitrite for the month-based
user/non-user separation. A: T-scores with respect to the population norm mean
and B: T-scoresample with respect to the sample means
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Fig 10. Average personality profiles for Crack for the week-based
user/non-user separation. A: T-scores with respect to the population norm mean
and B: T-scoresample with respect to the sample means
testing 153 pairs of drug usages in order to estimate the significance of the
correlation [89]. We apply the most conservative technique, the Bonferroni correction,
and used the Benjamini-Hochberg (BH) step-up procedure [89] to control the False
Discovery Rate (FDR) in order to estimate the genuine significance of these
correlations. There are 115 significant correlation coefficients with Bonferroni
corrected p-value 0.001. The BH step-up procedure with threshold of FDR equal to
0.01 defines 127 significant correlation coefficients.
However, a significant correlation does not necessarily imply a strong association or
causality. For example, the correlation coefficient for alcohol usage and amyl nitrate
usage is significant (i.e. the p-value is equal to 0.0013) but the value of this coefficient
is equal to 0.074, and thus cannot be considered as an important association. We
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consider correlations with absolute values of PCC |r| ≥ 0.4. Fig 11 sets out all
significant identified correlations greater than 0.4. In this study for the decade-based
classification problem we consider the correlation as weak if |r| < 0.4, medium if
0.45 > |r| ≥ 0.4, strong if 0.5 > |r| ≥ 0.45 ,and very strong if |r| ≥ 0.5.
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Fig 11. Strong drug usage correlations: A: for the decade-based classification
problem and B: for the year-based classification problem
The correlation coefficient is high for each pair from the group: amphetamines,
cannabis, cocaine, ecstasy, ketamine, legal highs, LSD, and magic mushrooms,
excluding correlations between cannabis and ketamine usage (r=0.302) and between
legal highs and ketamine usage (r=0.393) (Fig 11A). Crack, benzodiazepines, heroin,
methadone, and nicotine usages are correlated with one, two, or three other drugs
usage (see Fig 11A). Alcohol, amyl nitrite, chocolate, and caffeine usage and VSA are
uncorrelated or weakly correlated with usage of all other drugs.
The structure of correlations of the year-based user/non user separation are
approximately the same as for the decade-based classification problem (see Fig 11).
We consider correlations with absolute values of PCC |r| ≥ 0.35 for the year-based
classification. Fig 11B sets out all identified significant correlations with |r| > 0.35.
The correlation can be interpreted as weak if |r| < 0.35; medium if 0.40 > |r| ≥ 0.35;
strong if 0.5 > |r| ≥ 0.40; and very strong if |r| ≥ 0.5. On base of this similarity of
correlation structures we define pleiades for three central drugs: heroin, ecstasy, and
benzodiazepines (as described in the ‘Pleiades of drugs’ Section).
Relative Information Gain (RIG) is widely used in data mining to measure
dependence between categorical attributes [90]. The greater the value of RIG is, the
stronger is the indicated correlation. RIG is zero for independent attributes, is not
symmetric and is a measure of mutual information. For example, the value of RIG for
drug 1 usage from usage of drug 2 is equal to a fraction of uncertainty (entropy) in
drug 1 usage, which can be removed if the value of drug 2 usage is known. The
significance of RIG for binary random variables is the same as for PCC. The majority
of RIGs are significant, but have small values. Fig 12 presents all pairs with RIG
>0.15.
Fig 12A shows ‘approximately symmetric’ RIGs. Here, we call RIG(X |Y )
approximately symmetric if
|RIG(X |Y )− RIG(Y |X)|
min (RIG(X |Y ),RIG(Y |X)) < 0.2.
RIG is approximately symmetric for each pair from the following group:
amphetamines, cannabis, cocaine, ecstasy, legal highs, LSD and magic mushrooms.
This group is the same that in Fig 11 (except ketamine). Fig 12B shows asymmetric
RIGs. Asymmetric RIGs illustrate pattern significantly different from Fig 11.
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Fig 12. Pairs of drug usages with high RIG: A: approximately symmetric RIG
and B: significantly asymmetric RIG. In figure B arrow from cocaine usage to heroin
usage, for example, means that knowledge of cocaine usage can decrease uncertainty in
heroin usage.
Input feature ranking
It should be stressed that FFM, impulsivity, and sensation-seeking are all correlated.
To identify the most informative features we apply several methods which are
described in the ‘Input feature ranking’ Section. The results of the principal variables
calculation are represented in Table 13 for CatPCA quantification, and in Table 14 for
dummy coding of nominal features. Tables 13 and 14 contain the lists of attributes in
order from best to worst. The results of Double Kaiser’s ranking are shown in the
same tables.
Table 13. Results of feature ranking. Data include country of residence and ethnicity quantified by CatPCA. FVE is the
fraction of explained variance. CFVE is the cumulative FVE. The least informative features are lower located.
Principal variable ranking Double Kaiser’s ranking
Attribute FVE CFVE
Sensation-seeking 0.192 0.192 Extraversion
Neuroticism 0.153 0.345 Conscientiousness
Agreeableness 0.106 0.451 Sensation-seeking
Education 0.104 0.555 Neuroticism
Openness 0.092 0.647 Impulsivity
Conscientiousness 0.088 0.735 Openness
Extraversion 0.076 0.811 Agreeableness
Age 0.073 0.884 Age
Impulsivity 0.055 0.939 Education
Country 0.037 0.976 Country
Gender 0.021 0.997 Gender
Ethnicity 0.003 1.000 Ethnicity
The results of application of sparse PCA are shown in Tables 15 and 16. As a
result of feature selection we can exclude ethnicity from further consideration. There
is a more intriguing effect regarding country of location. Only two countries are
informative (in our sample): UK and USA. Furthermore, including country in
personality measures does not add much to the prediction of drug use. To understand
the reasons for these two countries’ importance in the prediction of drug consumption
we compare the statistics for the subsamples: UK - non-UK and USA - non-USA. We
calculated the p-value of coinciding distribution of personality measurements in each
subsample. We obtained the same results for both divisions into subsamples: all input
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Table 14. Results of feature ranking. Data include dummy coded country of residence and ethnicity. FVE is the fraction
of explained variance. CFVE is the cumulative FVE. The least informative features are lower located.
Principal variable ranking Double Kaiser’s ranking
Attribute FVE CFVE
Sensation-seeking 0.186 0.186 Extraversion
Neuroticism 0.149 0.335 Conscientiousness
Agreeableness 0.103 0.438 Sensation-seeking
Education 0.101 0.539 Neuroticism
Openness 0.089 0.627 Impulsivity
Conscientiousness 0.086 0.714 Openness
Extraversion 0.074 0.787 Agreeableness
Age 0.071 0.858 Age
Impulsivity 0.053 0.911 Education
UK 0.027 0.938 UK
Gender 0.020 0.959 USA
USA 0.013 0.972 Gender
White 0.010 0.982 Other (country)
Other (country) 0.005 0.988 White
Canada 0.004 0.991 Other (ethnicity)
Other (ethnicity) 0.003 0.994 Canada
Black 0.002 0.995 Asian
Australia 0.002 0.997 Mixed-White/Black
Asian 0.001 0.998 Australia
Mixed-WhiteBlack 0.001 0.999 Black
Republic of Ireland 0.000 1.000 Mixed-White/Asian
Mixed-WhiteAsian 0.000 1.000 Republic of Ireland
New Zealand 0.000 1.000 New Zealand
Mixed-BlackAsian 0.000 1.000 Mixed-Black/Asian
features have significantly different distributions with a 99.9% confidence level for UK
and non-UK subsamples and likewise for USA – non-USA subsamples. This means
that the UK and non-UK samples are biased. The same situation is found for the USA
and non-USA samples.
To understand the importance of these features for evaluating of the risk of drug
consumption we perform a simple analysis of these two features for the classification of
users and non-users for all drugs (see Table 17). Table 17 allows us to conclude that
chocolate is UK specific drug, crack heroin, legal highs, LSD, magic mushrooms,
methadone and VSA are USA specific drugs and all drugs excluding alcohol, amyl
nitrite, caffeine and chocolate are mostly used out of UK. Unfortunately, this
conclusion is mainly due to the composition of the dataset: participants from the UK
(1044; 55.4%), the USA (557; 29.5%), Canada (87; 4.6%), Australia (54; 2.9%), New
Zealand (5; 0.3%) and Ireland (20; 1.1%). A total of 118 (6.3%) came from a diversity
of other countries, none of whom individually formed 1% of the sample, or did not
declare the country of location.
Our goal is to predict the risk of drug consumption for an individual. This means
that we have to consider individual specific factors. Occupation within a specific
country can be considered as important risk factor but we do not have enough data for
countries other than UK and USA. We exclude the country feature from further study
for these reasons. As a result, for further study we have 10 input features: age, Edu.,
N, E, O, A, C, Imp., SS, and gender.
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Table 15. The result of sparse PCA feature ranking. Data include country of residence and ethnicity quantified by
CatPCA.
Step # of components Removed attributes
1 5 Gender and Ethnicity
2 4 No removed attributes. The retained set of attributes: age, Edu.,
N, E, O, A, C, Imp. SS, and country
Table 16. The result of sparse PCA feature ranking. Data include dummy coded country of residence and ethnicity.
Step # of components Removed attributes
1 8 Canada , Other (country), Australia, Republic of Ireland, New Zealand,
Mixed-White/Asian, White, Other (ethnicity), Mixed-White/Black, Asian,
Black and Mixed-Black/Asian
2 5 Gender, UK and USA
3 4 No removed attributes. The retained set of attributes: age, Edu., N, E, O,
A, C, Imp. and SS
Table 17. Analysis of UK and USA categories of feature country of residence as a classifier into users and non-users for the
decade-based classification for all drugs.
Drug UK means user UK means non-user USA means user USA means non-user
Sens. Spec. Sens. Spec. Sens. Spec. Sens. Spec.
(%) (%) (%) (%) (%) (%) (%) (%)
Alcohol 55 38 45 62 30 81 70 19
Amphetamines 32 31 68 69 48 81 52 19
Amyl nitrite 61 46 39 54 19 68 81 32
Benzodiazepines 33 29 67 71 49 84 51 16
Caffeine 55 16 45 84 30 86 70 14
Cannabis 40 12 60 88 42 95 58 5
Chocolate 56 63 44 37 29 54 71 46
Cocaine 38 35 62 65 44 79 56 21
Crack 24 41 76 59 59 74 41 26
Ecstasy 35 31 65 69 45 81 55 19
Heroin 16 40 84 60 68 75 32 25
Ketamine 42 42 58 58 37 72 63 28
Legal highs 30 28 70 72 51 85 49 15
LSD 20 30 80 70 56 82 44 18
MMushrooms 26 27 74 73 53 84 47 16
Methadone 17 34 83 66 67 81 33 19
Nicotine 46 26 54 74 37 85 63 15
VSA 20 40 80 60 63 75 37 25
Selection of the best classifiers for the decade based
classification problem
The first step for the risk evaluation is the construction of classifiers. We tested the
eight methods described in the ‘Risk evaluation methods’ Section and selected the best
one. The results of the classifier selection are presented in Table 18. This table shows
that for all drugs except alcohol, cocaine and magic mushrooms, the sensitivity and
specificity are greater than 70%, which is an unexpectedly high accuracy.
Recall that we have 10 input features: age, Edu., N, E, O, A, C, Imp., SS, and
gender; each of them is an important predictor for at least five drugs. However, there
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is no single most effective classifier which uses all input features. The maximal number
of used attributes is six out of 10 and the minimal number is two. In Section
‘Criterion of the best method selection’ the best method is defined as the method
which maximises value of the minimum of sensitivity and specificity. If the minimum
of sensitivity and specificity is the same for two classifiers then the classifier with the
maximal sum of the sensitivity and specificity is selected from them. Table 18 shows
which different sets of attributes are used in the best user/non usser classifier for each
different drugs.
Table 18. The best results of the drug users classifiers. Symbol ‘X’ means the used input feature. Results are calculated
by LOOCV.
Target feature Classifier Age Edu. N E O A C Imp. SS Gender Sens. Spec. Sum
(%) (%) (%)
Alcohol LDA X X X X X 75.34 63.24 138.58
Amphetamines DT X X X X X X 81.30 71.48 152.77
Amyl nitrite DT X X X X 73.51 87.86 161.37
Benzodiazepines DT X X X X X X 70.87 71.51 142.38
Cannabis DT X X X X X X 79.29 80.00 159.29
Chocolate kNN X X X X 72.43 71.43 143.86
Cocaine DT X X X X X 68.27 83.06 151.32
Caffeine kNN X X X X X 70.51 72.97 143.48
Crack DT X X 80.63 78.57 159.20
Ecstasy DT X X X 76.17 77.16 153.33
Heroin DT X X X 82.55 72.98 155.53
Ketamine DT X X X X X 72.29 80.98 153.26
Legal highs DT X X X X X X 79.53 82.37 161.90
LSD DT X X X X X X 85.46 77.56 163.02
Methadone DT X X X X X 79.14 72.48 151.62
MMushrooms DT X X 65.56 94.79 160.36
Nicotine DT X X X X 71.28 79.07 150.35
VSA DT X X X X X X 83.48 77.64 161.12
The use of a feature in the best classifier can be interpreted as ‘ranking by fact’.
We can note that this ranking by fact is very different from other rankings presented
in Tables 13 and 15. For example, age is shown not to be the most informative
measure in accordance with Tables 13 and 15, but it is used in the best classifiers for
14 drugs. The second most used input feature is gender, which is considered as
non-informative by Sparse PCA (Table 15) and as one of the least informative by
other methods (Table 13). This means that consumption of these 10 drugs is gender
dependent. We found some unexpected outcomes: for example, in the dataset the
fraction of females who are alcohol users is greater than that fraction of males (Fig 13)
but the greater proportion of males drink coffee (Fig 14). The fraction of males who
do not eat chocolate is greater than for females (Fig 15). The conditional distributions
for nicotine meets the common sense expectations (Fig 16).
The next most informative input features are E and SS which are used in the best
classifiers for nine drugs. Features O, C, and Imp. are used in the best classifiers for
eight drugs. Features N and A are used in the best classifiers for six drugs. Thus,
personality factors are associated with drug use and each one impacts on specific
drugs. Finally, Edu. is used in the best classifiers for five drugs (see Table 18).
To predict the usage of the most drugs DT is the best classifier (see Table 18). LDA
is the best classifier for alcohol use with five input features, and has sensitivity 75.34%
and specificity 63.24%. kNN is the best classifier for chocolate and caffeine users.
These kNN classifiers use four features for chocolate and five features for caffeine.
The drugs can be separated into disjoint groups by the number of attributes used
for the best classifiers:
• The group of classifiers with two input features contains classifiers for two drugs:
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Fig 15. Conditional distribution for gender and chocolate.
crack and magic mushrooms. Both classifiers of this group use the E score.
• The group of classifiers with three input features includes classifiers for two
drugs: ecstasy and heroin. Both classifiers in this group use age and gender and
do not use any NEO-FFI factors.
• The group of classifiers with four input features includes classifiers for three
drugs: amyl nitrite, chocolate, and nicotine. All classifiers of this group use the
C score.
• The group of classifiers with five input features includes classifiers for five drugs:
alcohol, cocaine, caffeine, ketamine, and methadone. All classifiers of this group
use age.
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• The group of classifiers with six input features includes classifiers for six drug
users: amphetamines, benzodiazepines, cannabis, legal highs, LSD, and VSA. All
classifiers of this group use age.
It is important to stress that the attributes which are not used in the best classifiers
are not non-informative. For example, for ecstasy consumption the best classifier is
based on age, SS, and gender and has sensitivity 76.17% and specificity 77.16%. There
exist a DT for usage of the same drug based on age, Edu., O, C, and SS with
sensitivity 77.23% and specificity 75.22%, a DT based on age, Edu., E, O, and A with
sensitivity 73.24% and specificity 78.22%, a LR classifier based on age, Edu., O, C,
Imp., SS, and gender with sensitivity 74.83% and specificity 74.52%, and a kNN
classifier based on age, Edu., N, E, O, C, Imp., SS, and gender with sensitivity 75.63%
and specificity 75.75%. This means that for the risk evaluation of ecstasy usage all
input attributes are informative but the required information can be extracted from a
smaller subset of the attributes.
The results presented in Table 18 were calculated by LOOCV. It should be stressed
that the different methods of testing give different sensitivity and specificity. Common
methods include calculation of test set errors (the holdout method), k-fold
cross-validation, testing on the entire sample (if it is sufficiently large, so-called ‘na¨ıve’
method), random sampling, and many others. For example, a DT formed for the
entire sample can have a sensitivity and specificity different from LOOCV [85]. For
illustration, consider the DT for ecstasy, depicted in the Fig 17. It has sensitivity
78.56% and specificity 71.16%, calculated using the whole sample. The results of
LOOCV for a tree with the same options are presented in the Table 18: sensitivity
76.17% and specificity 77.16%.
The role of SS is very important for most of the party drugs. In particular, the risk
of ecstasy consumption can be evaluated with high accuracy on the basis of age,
gender and SS (see Table 18, Fig 17, and 22), and does not need the personality traits
from five factors model.
Pleiades of drugs
Consider correlations between drug usage for the year- and decade-based definitions
(Fig 11). It can be seen from Fig 11 that the structure of these correlations for the
year- and decade-based definitions of drug users is approximately the same. We found
three groups of strongly correlated drugs, each containing several drugs which are
pairwise strongly correlated. This means that drug consumption has a ‘modular
structure’. Let us consider a modular structure for the three modules we found:
• Crack, cocaine, methadone, and heroin;
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Fig 17. Decision tree for ecstasy. Input features are: age, SS, and gender.
Non-terminal nodes are depicted with dashed border. Values of age, SS, and gender
are calculated by quantification procedures described in the ‘Input feature
transformation’ Section. Weight of each case of users class is 1.15 and of non-users
class is 1. Column ‘Weighted’ presents normalized weights: weight of each class is
divided by sum of weights.
• Amphetamines, cannabis, cocaine, ketamine, LSD, magic mushrooms, legal
highs, and ecstasy;
• Methadone, amphetamines, cocaine and benzodiazepines.
The modular structure has clear reflection in the correlation graph, Fig 11.
The idea of merging correlated attributes into ‘modules’ is popular in biology
These modules are called the ‘correlation pleiades’ [35–37]. The concept of correlation
pleiades was introduced in biostatistics in 1931 [35]. Correlation pleiades were used in
evolutionary physiology for the identification of the modular structure [35–38]. Berg
presented correlation data from three unspecialized and three specialized pollination
species. According to Berg [37], correlation pleiades are clusters of correlated traits.
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This means that in the standard approach to clustering the pleiads do not intersect.
The classical clustering methods are referred to as ‘hard’ or ‘crisp’ clustering, meaning
that each data object is assigned to only one cluster. This restriction is relaxed for
fuzzy [40] and probabilistic clustering [39]. Such approaches are useful when the
boundaries between clusters are not well separated.
In our study, correlation pleiades can be applied since the drugs can be grouped in
clusters with highly correlated use (see Fig 11A and 11B):
• The Heroin pleiad (heroinPl) includes crack, cocaine, methadone, and heroin;
• The Ecstasy pleiad (ecstasyPl) includes amphetamines, cannabis, cocaine,
ketamine, LSD, magic mushrooms, legal highs, and ecstasy;
• The Benzodiazepines pleiad (benzoPl) includes methadone, amphetamines, and
cocaine.
Fuzzy and probabilistic clustering may help to reveal more sophisticated
relationships between objects and clusters. For example, analysis of the intersections
between correlation pleiads of drugs can generate important question and hypotheses:
• Which patterns of behaviour are reflected by the existence of pleiades? (For
example, is the ecstasyPl just the group of party drugs united by traditions of
use?)
• Why is cocaine a peripheral member of all pleiads?
• Why does methadone belong to the periphery of both the heroin and
benzodiazepines pleiades?
• Why does amphetamines belong to the periphery of both the ecstasy and
benzodiazepines pleiades?
• Do these intersections reflect the structure of individual drug consumption or the
structure of the groups of drug consumers?
We define groups of users and non-users for each pleiad. A group of users for a
pleiad includes the users of any individual drugs from the pleiad (see Table 19). A
group of non-users contains all participants which are not included in the group of
users. Table 19 presents the total number of users and their percentages in the
database for three pleiades and for different definition of users (the decade-, year-,
month-, or week-based user/non-user separation).
The class imbalance problem is well known [85]. Users form a small fraction of the
dataset (significantly less than the half) for most of drugs (see Table 1). The classes of
users and non-users are more balanced for pleiades of drugs than for individual drugs
(compare Table 19 and 1). Table 19 shows that the number of drug users in the
database for all three pleiades are more balanced (close to 50%) than the number of
users of the corresponding individual drug (Table 1). For example, for the
decade-based classification problem the number of benzoPl users is 1089 (57.77%),
while the number of benzodiazepines users is 769 (40.80%) and the number of heroinPl
users is 832 (44.14%), while the number of heroin users is 212 (11.25%).
The introduction of moderate subcategories of T-scoresample for pleiades of drugs
enables to separates the pleiades of drugs into two groups for the decade-, month-, and
week-based user/non-user separation. While for year-based user/non-user separation it
is only one group with the profile (+, 0,+,−,−) includes the users of heroinPl,
ecstasyPl and benzoPl.
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Table 19. Number of drug users for pleiades in the database
Pleiad User definition based on
Decade Year Month Week
HeroinPl 832 (44.14%) 585 (31.03%) 309 (16.39%) 184 (9.76%)
EcstasyPl 1317 (69.87%) 1089 (57.77%) 921 (48.86%) 792 (42.02%)
BenzoPl 1089 (57.77%) 830 (44.03%) 528 (28.01%) 363 (19.26%)
Table 20. Significant differences of means for groups of users and non-users for each pleiad for decade- year-, month-, and
week-based classification problem . Symbol ‘ ⇓ ’ corresponds to significant difference where the mean in users group is less
than mean in non-users group and symbol ‘⇑ corresponds to significant difference where the mean in users group is greater
than the mean in non-users group. Empty cells corresponds to insignificant differences. Difference is considered as
significant if p-value is less than 0.01).
Pleiades od drugs N E O A C
The decade-based user/non user separation
HeroinPl, EcstasyPl, BenzoPl ⇑ ⇑ ⇓ ⇓
The year-based user/non user separation
HeroinPl, EcstasyPl, BenzoPl ⇑ ⇑ ⇓ ⇓
The month-based user/non user separation
HeroinPl, EcstasyPl ⇑ ⇑ ⇓ ⇓
BenzoPl ⇑ ⇓ ⇑ ⇓ ⇓
The week-based user/non user separation
HeroinPl, BenzoPl ⇑ ⇓ ⇑ ⇓ ⇓
EcstasyPl ⇑ ⇑ ⇓ ⇓
For decade-based classification problem, the group with the profile (+, 0,+,−,−)
includes the users of heroinPl and benzoPl. The group with the profile (0, 0,+,−,−)
includes the users of EcstasyPl.
For month- and week-based classification problem, the group with the profile
(+,−,+,−,−) includes the users of heroinPl and benzoPl. The group with the profile
(0, 0,+,−,−) includes the users of EcstasyPl.
The personality profile for pleiades of drugs also are strongly associated with
belonging to groups of the users and non-users of each plead for decade-, year-,
month-, and week-based classification problem (see Fig. 18, Fig. 19, Fig. 20 and 21).
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Fig 18. Average personality profiles for HeroinPl for the Decade-based
user/non-user separation. A: T-scores with respect to the population norm mean
and B: T-scoresample with respect to the sample means
We applied the eight methods described in Section ‘Risk evaluation methods’ and
selected the best one for each pleiad for decade-, year-, month-, and week-based
classification problem. The results of the classifier selection are depicted in Table 21
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Fig 20. Average personality profiles for BenzoPl for the month-based
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user/non-user separation. A: T-scores with respect to the population norm mean
and B: T-scoresample with respect to the sample means
and the quality of classification is high.
The classification results are very satisfactory for each pleiad for decade-, year-,
month, and week based problem. We can compare the classifiers for one pleiad and for
different problems (see Table 21). For example,
• The best classifier for ecstasyPl for the year-based user/non user separation is
DT with seven attributes and has sensitivity 80.65% and specificity 80.72%.
• The best classifier for heroinPl for the month-based user/non user separation is
DT with five attributes and has sensitivity 74.18% and specificity 74.11%.
• The best classifier for benzoPl for the week-based user/non user separation is
DT with five attributes and has sensitivity 75.10% and specificity 75.76%.
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Table 21. The best results of the pleiad users classifiers. Symbol ‘X’ means input feature used in the best classifier.
Sensitivity and Specificity were calculated by LOOCV.
Pleiades Classifier Age Edu. N E O A C Imp. SS Gender # Sens. Spec. Sum
of drugs (%) (%) (%)
The decade-based user/non user separation
HeroinPl DT X X X X 4 71.23 78.85 150.07
EcstasyPl DT X X X X X X 6 80.63 79.80 160.44
BenzoPl DT X X X X X 5 73.37 72.45 145.82
The year-based user/non user separation
HeroinPl DT X X X X 4 73.69 71.80 145.49
EcstasyPl DT X X X X X X X 7 80.65 80.72 161.37
BenzoPl DT X X X X 4 73.93 73.98 147.91
The month-based user/non user separation
HeroinPl DT X X X X X 5 74.18 74.11 148.29
EcstasyPl PDFE X X X X X X X X 8 79.34 79.50 158.83
BenzoPl DT X X X X 4 73.18 73.11 146.28
The week-based user/non user separation
HeroinPl DT X X X X X X X X 8 75.84 73.91 149.75
EcstasyPl LR X X X X X X X X 8 77.68 77.78 155.45
BenzoPl DT X X X X X 5 75.10 75.76 150.86
The comparison of Tables 18 and 21 shows that the best classifiers for the ecstasy
and benzodiazepines pleiades are more accurate than the best classifiers for
consumption of the ‘central’ drugs of the pleiades, ecstasy and benzodiazepines even
for the decade-based user definition. Classifiers for heroinPl may have slightly worse
accuracy but these classifiers are more robust because they solve classification
problems which have more balanced classes. All other classifiers for pleiades of drugs
are more robust too by the same reasons for all pleiades and definitions of users.
Tables 18 and 21 for the decade-based user definition show that most of the
classifiers for pleiades use more input features than the classifiers for individual drugs.
We can see from these tables that the accuracies of the classifiers for pleiades and for
individual drugs do not differ drastically, but the use of a greater number of input
features indicates more robust classifiers.
It is important to stress that usually pleiades are assumed to be disjoint. We
consider pleiades which are named by the central drug and have an intersection in the
peripheral drugs. For example, heroin and ecstasy pleiades have cocaine as an
intersection. This approach corresponds to the concept of ‘soft clustering’.
Risk evaluation for the decade-based user/non user separation
The successful construction of a classifier provides an instrument for the evaluation of
the risk of drug consumption for each individual, along with the creation of a map of
risk [91, 92]. The risk map of ecstasy consumption on the basis of three input features
is depicted in Fig 22. From the PDFE-based risk maps (Fig 22A and 22B) it can be
observed that there is a considerable area of high risk (indicated in blue) for men aged
between 25-34 years, but significantly less for females. However, young males with the
highest SS scores have significantly less risk than females with the same profiles.
DT-based risk maps (Fig 22C and 22D) illustrate qualitatively the same shapes. The
risk maps provide a tool for the generation of hypotheses for further study. We can
create risk maps for pleiades of drugs as well.
Summary
Our study demonstrates strong correlations between personality profiles and the risk
of drug use. This result supports observations from some previous
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Fig 22. Risk map of ecstasy consumption for: A & C: female and B & D: male; A
& B: PDFE-based map and C & D: DT-based map; E: Legend of colours
works [3, 12–14,16–19]. Individuals involved in drug use are more likely to have higher
scores for N, and low scores for A and C . We analysed in detail the average
differences in the groups of drug users and non-users for 18 drugs (Tables 5, 6, 7, and
8). In addition to this analysis, we achieved much more detailed knowledge about the
relationship between the personality traits, biographic data and the use of individual
drugs or drug clusters by an individual patient.
The analysed database contained 1885 participants and 12 features (input
attributes). These features included five personality traits (NEO-FFI-R); impulsivity
(BIS-11), sensation seeking (ImpSS), level of education, age, gender, country of
residence, and ethnicity. The data set included information on the consumption of 18
central nervous system psychoactive drugs: alcohol, amphetamines, amyl nitrite,
benzodiazepines, cannabis, chocolate, cocaine, caffeine, crack, ecstasy, heroin,
ketamine, legal highs, LSD, methadone, mushrooms, nicotine, and VSA (output
attributes). There were limitations of this study since the collected sample was biased
with respect to the general population, but it remained useful for risk evaluation.
We used three different techniques of feature ranking. After input feature ranking
we excluded ethnicity and country of residence. It was impossible to completely
exclude the possibility that ethnicity and country of residence may be important risk
factors, but the dataset has not enough data for most of ethnicities and countries to
prove the value of this information. As a result, 10 input features remained: age, Edu.,
N, E, O, A, C, Imp., SS, and gender. Our aim was to predict the risk of drug
consumption for an individual.
All input features are ordinal or nominal. To apply data mining methods which
were developed for continuous input features we apply CatPCA technique to quantify
data.
We used four different definitions of drug users which differ with regard to the
recency of the last drug consumption: the decade-based, year-based, month-based and
week-based user/non user separation (Fig. 1). The day-based classification problem is
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also possible but there is not enough data on drug use during the last day for most
drugs
Our findings allowed us to draw a number of important conclusions about the
associations between personality traits and drug use. All five personality factors are
relevant traits to be taken into account when assessing the risk of drug consumption.
The mean scores for the groups of users of all 18 drugs are moderately high (+) or
neutral (0) for N and O, and moderately low (−) for A and C, except for crack usage
for the week based classification problem which has a moderately low (−) O score (see
Table 8 and Fig 10). Users of legal drugs (alcohol, chocolate, caffeine, and nicotine)
have neutral A and C scores (0), except nicotine users whose C score is moderately low
(−). For LSD users in the year based classification problem and for LSD and magic
mushrooms users in the week based classification problem the A score is neutral (0).
The impact of the E score is drug specific. For example, for the decade-based
user/non user definition the E score is negatively correlated with consumption of
crack, heroin, VSA, and methadone (E score is (−) for their users). It is has no
predictive value for other drugs for the decade-based classification (E score for users is
(0)), whereas in the year-, month-, and week-based classification problems all three
possible values of E score are observed (see Tables 5, 6, 7 and 8).
We confirm the previous researcher finding that the higher scores for N and O the
lower scores for C and A lead to increased risk of drug use [20]. O score is marked by
curiosity and open-mindedness (and correlated with intelligence), and it is therefore
understandable why higher O may be sometimes associated with drug use [93]. Flory
et al [14] found that marijuana use to be associated with lower A and C, and higher O.
These findings have been confirmed by our study. Our results improve the knowledge
concerning the pathways leading to drug consumption.
It is known that significant predictors of alcohol, tobacco and marijuana use may
vary according to the drug in question [94]. Our study demonstrated that different
attributes were important for different drugs. We tested eight types of classifiers for
each drug for the decade-based user definition. LOOCV was used to evaluate
sensitivity and specificity. In this study we choose the method which provide maximal
value of minimum among sensitivity and specificity as the best one. The method with
maximal sum of the sensitivity and specificity is selected as the best one for two
methods with the same minimum among sensitivity and specificity. There were
classifiers with sensitivity and specificity greater than 70% for the decade-based
user/non user separation for all drugs except magic mushrooms, alcohol, and cocaine
(Table 18). This accuracy was unexpectedly high for this type of problem. The
poorest result was obtained for the prediction of alcohol consumption.
The best set of input features was defined for each drug (Table 18). An exhaustive
search was performed to select the most effective subset of input features, and the best
data mining methods to classify users and non-users for each drug. There were 10
input features. Each of them is an important factor for risk evaluation for the use of
some drugs. However, there was no single most effective classifier using all input
features. The maximal number of attributes used in the best classifiers is six (out of
10) and the minimal number is two.
Table 18 shows the best sets of attributes for user/nonuser classification for
different drugs and for the decade-based classification problem. This table together
with its analogues for pleiads of drugs and all decade-year-month-week classification
problems (Table 21) are important result of the analysis.
The DT for crack consumption used two features E and C only, and provided
sensitivity of 80.63% and specificity of 78.57%. The DT for VSA consumption used
age, Edu., E, A, C, and SS, and provided sensitivity 83.48% and specificity 77.64%
(Table 18).
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Age was a widely used feature which was employed in the best classifiers for 14
drugs for the decade-based classification problem. Gender was used in the best
methods for 10 drugs. We found some unexpected outcomes. For example, fraction of
females which are alcohol users is greater than the fraction of males but the greater
part of males consume caffeine (coffee).
Most of the features which are not used in the best classifiers are redundant but
are not uninformative. For example, the best classifier for ecstasy consumption used
age, SS, and gender and had sensitivity 76.17% and specificity 77.16%. There exist a
DT for prediction of usage of the same drug, which utilizes age, Edu., O, C, and SS
with sensitivity 77.23% and specificity 75.22%, a DT with inputs age, Edu., E, O, and
A with sensitivity 73.24% and specificity 78.22%, and an advanced kNN classifier with
inputs age, Edu., N, E, O, C, Imp., SS, and gender with sensitivity 75.63% and
specificity 75.75%. This means that for evaluating the risk of ecstasy usage all input
attributes are informative but the required information can be extracted from a subset
of attributes.
We demonstrated that there are three groups of drugs with strongly correlated
consumption. That is, the drug usage has a ‘modular structure’. The idea to merge
correlated attributes into ‘modules’ is popular in biology. The modules are called the
‘correlation pleiades’ [35–37] (see Section ‘Pleiades of drugs’). The modular structure
contains three modules: the heroin pleiad, ecstasy pleiad, and benzodiazepines pleiad:
• The Heroin pleiad (heroinPl) includes crack, cocaine, methadone, and heroin.
• The Ecstasy pleiad (ecstasyPl) includes amphetamines, cannabis, cocaine,
ketamine, LSD, magic mushrooms, legal highs, and ecstasy.
• The Benzodiazepines pleiad (benzoPl) includes contains methadone,
amphetamines, and cocaine.
The modular structure has a clear reflection in the correlation graph, Fig 11. We
define groups of users and non-users for each pleiad. In most of the databases the
classes of users and non-users for most of the individual drugs are imbalanced (see
Table 2) but the merging the users of all drugs in one class ‘drug users’ does not seem
to be the best solution because of physiological, psychological and cultural differences
between usage of different drugs. We propose instead to use correlation pleiades for
the analysis of drug usage as a solution to the class imbalance problem because for all
three pleiades the classes of users and non-users are better balanced (Table 19) and
the consumption of different drugs from the same pleiad is correlated.
We applied the eight methods described in the ‘Risk evaluation methods’ Section
and selected the best one for each problem for all pleiades. The results of the classifier
selection are presented in Table 21 and the quality of the classification is high. The
majority of the best classifiers for pleiades of drugs has a better accuracy than the
classifiers for individual drug usage. (see Table 18 and 21). The best classifiers for
pleiades of drugs use more input features than the best classifiers for the
corresponding individual drugs. The classification problems for pleiades of drugs are
more balanced. Therefore, we can expect that the classifiers for pleiades are more
robust than the classifiers for individual drugs.
The user/non-user classifiers can be also used for forming of risk maps. Risk maps
are useful tools for data visualisation and hypotheses generation.
Discussion
These results are important as they examine the question of the relationship between
drug use and personality comprehensively and engage the challenge of untangling
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correlated personality traits (the FFM, impulsivity, and sensation seeking [95]), and
clusters of substance misuse (the correlation pleiades). The work acknowledged the
breadth of a common behaviour which may be transient and leave no impact, or may
significantly harm an individual. We examined drug use behaviour comprehensively in
terms of the many kinds of substances that may be used (from the legal and anodyne,
to the deeply harmful), as well as the possibility of behavioural over-claiming. We
built into our study the wide temporality of the behaviour indicative of the chronicity
of behaviour and trends and fashions (e.g. the greater use of LSD in the 1960s and
1970s, the rise of ecstasy in the 1980s, some persons being one-off experimenters with
recreational drugs, and others using recreational substances on a daily basis).
We defined substance use in terms of behaviour rather than legality, as legislation
in the field is variable. Our data were gathered before ‘ legal highs’ emerged as a
health concern [96] so we did not differentiate, for example, synthetic cannabinoids
and cathinone-based stimulants; these substances have been since widely made illegal.
We were nevertheless able to accurately classify users of these substances (reciprocally,
our data were gathered before cannabis decriminalisation in parts of North America,
but again, we were able to accurately classify cannabis users). We included control
participants who had never used these substances, those who had used them in the
distant past, up to and including persons who had used the drug in the past day,
avoiding the procrustean data-gathering and classifying methods which may occlude
an accurate picture of drug use behaviour and risk [97]. Such rich data and the
complex methods used for analysis necessitated a large and substantial sample.
The study was atheoretical regarding the morality of the behaviour, and did not
medicalise or pathologise participants, optimising engagement by persons with
heterogeneous drug-use histories. Our study used a rigorous range of data-mining
methods beyond those typically used in studies examining the association of drug use
and personality in the psychological and psychiatric literature, revealing that decision
tree methods were most commonly effective for classifying drug users. We found that
high N, low A, and low C are the most common personality correlates of drug use,
these traits being sometimes seen in combination as an indication of higher-order
stability and behavioural conformity, and, inverted, are associated with externalisation
of distress [98–100].
Low stability is also a marker of negative urgency [47] whereby persons act rashly
when distressed. Our research points to the importance of individuals acquiring
emotional self-management skills anteceding distress as a means to reduce
self-medicating drug-using behaviour, and the risk to health that injudicious or
chronic drug use may cause.
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Supporting Information
S1 Appendix. Mean for groups of users and non-users. In this section we
present mean T-scoresample for groups of users and non-users for decade, year, month,
and week based user definitions respectively. Column p-value assesses the significance
of differences of mean scores for groups of users and non-users: it is the probability of
observing by chance the same or greater differences for mean scores if both groups
have the same mean. Rows ‘#’ contain number of users and non-users for the drugs.
Table 22. Mean T-scoresample and 95% CI for it for groups of users and non-users with decade based definition of users
Factor Users Non-users p-value
Mean T-score 95% CI for mean Mean T-score 95% CI for mean
Alcohol
# 1817 68
N 50.13 49.67, 50.59 48.19 45.77, 50.61 0.116
E 50.06 49.60, 50.52 50.04 47.61, 52.42 0.988
O 50.04 49.58, 50.51 48.81 46.45, 51.17 0.318
A 49.93 49.47, 50.39 52.51 50.26, 54.77 0.036
C 49.94 49.48, 50.40 53.31 51.05, 55.56 0.006
Amphetamines
# 679 1206
N 51.71 50.95, 52.46 49.14 48.58, 49.69 0.001
E 49.71 48.89,50.53 50.26 49.72, 50.80 0.251
O 53.05 52.34, 53.77 48.28 47.72, 48.84 0.001
A 48.39 47.60, 49.18 50.94 50.39, 51.48 0.001
C 47.04 46.29, 47.80 51.76 51.22, 52.30 0.001
Amyl nitrite
# 370 1515
N 50.78 49.78, 51.79 49.89 49.37, 50.39 0.122
E 50.97 49.95, 51.99 49.84 49.33, 50.35 0.052
O 51.45 50.47, 52.43 49.65 49.14, 50.15 0.002
A 48.69 47.65, 49.72 50.35 49.84, 50.85 0.004
C 48.08 46.10, 49.07 50.54 50.04, 51.05 0.001
Benzodiazepines
# 769 1116
N 52.83 52.12, 53.54 48.15 47.59, 48.72 0.001
E 49.07 48.31, 49.83 50.74 50.19, 51.30 0.001
O 52.66 51.97, 53.34 48.17 47.59, 48.75 0.001
A 48.28 47.53, 49.02 51.22 50.67, 51.78 0.001
C 47.70 46.98, 48.41 51.69 51.12, 52.25 0.001
Cannabis
# 1265 620
N 51.08 50.52, 51.65 47.98 47.25, 48.71 0.001
E 49.75 49.17, 50.33 50.70 49.98, 51.41 0.053
O 52.48 51.96, 52.99 44.95 44.20,45.70 0.001
A 48.84 48.28,49.40 52.42 51.69,53.15 0.001
C 48.15 47.60,48.70 53.92 53.27,54.65 0.001
Chocolate
# 1850 35
N 50.06 49.60, 50.51 50.29 46.36, 54.21 0.894
Continued on the next page
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Table 22. Continued
Factor Users Non-users p-value
Mean T-score 95% CI for mean Mean T-score 95% CI for mean
E 50.05 49.59, 50.51 50.80 47.71, 53.89 0.660
O 50.05 49.59, 50.51 47.37 44.42, 50.32 0.117
A 50.05 49.59, 50.50 48.66 44.61, 52.70 0.416
C 50.03 49.58, 50.49 51.57 47.87, 55.27 0.366
Cocaine
# 687 1198
N 51.85 51.09, 52.60 49.04 48.48, 49.59 0.001
E 50.33 49.55, 51.12 49.91 49.35, 50.46 0.374
O 52.60 51.89, 53.30 48.51 47.94, 49.08 0.001
A 47.71 46.93, 48.50 51.34 50.81,51.88 0.001
C 47.49 46.76, 48.22 51.53 50.98, 52.09 0.001
Caffeine
# 1848 37
N 50.06 49.61, 50.52 50.08 46.59,53.57 0.991
E 50.13 49.67, 50.59 46.76 43.82, 49.69 0.043
O 50.11 49.65, 50.57 44.59 41.67,47.52 0.001
A 49.99 49.54, 50.45 51.11 47.71, 54.51 0.504
C 49.99 49.53, 50.44 53.59 50.79, 56.40 0.029
Crack
# 191 1694
N 53.08 51.64, 54.52 49.72 49.25, 50.20 0.001
E 48.80 47.33, 50.27 50.20 49.73, 50.68 0.066
O 52.91 51.60, 54.21 49.67 49.19, 50.15 0.001
A 47.02 45.46, 48.58 50.36 49.89, 50.83 0.001
C 46.19 44.70, 47.68 50.50 50.03, 50.96 0.001
Ecstasy
# 751 1134
N 51.30 50.58, 52.02 49.24 48.67, 49.82 0.001
E 50.56 49.80, 51.31 49.73 49.17, 50.30 0.081
O 53.62 52.96, 54.28 47.60 47.03, 48.17 0.001
A 48.49 47.75, 49.23 51.03 50.47, 51.60 0.001
C 47.30 46.59, 48.00 51.89 51.33, 52.45 0.001
Heroin
# 212 1673
N 54.60 53.29, 55.92 49.49 49.01, 49.96 0.001
E 48.42 46.94, 49.90 50.27 49.80, 50.74 0.011
O 54.25 53.04, 55.47 49.46 48.98, 49.94 0.001
A 45.53 44.00, 47.06 50.59 50.12, 51.05 0.001
C 45.91 44.55, 47.26 50.59 50.11, 51.06 0.001
Ketamine
# 350 1535
N 51.42 50.40, 52.43 49.75 49.25, 50.26 0.005
E 50.36 49.23, 51.48 49.99 49.50, 50.49 0.542
O 53.87 52.90, 54.84 49.12 48.62, 49.62 0.001
A 47.80 46.67, 48.94 50.53 50.04, 51.01 0.001
C 46.86 45.81, 47.92 50.79 50.30, 51.28 0.001
Legal highs
Continued on the next page
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Table 22. Continued
Factor Users Non-users p-value
Mean T-score 95% CI for mean Mean T-score 95% CI for mean
# 762 1123
N 51.49 50.77, 52.22 49.09 48.52, 49.66 0.001
E 49.71 48.94, 50.47 50.30 49.75, 50.86 0.206
O 54.30 53.67, 54.92 47.08 46.51, 47.65 0.001
A 48.61 47.86, 49.36 50.98 50.42, 51.53 0.001
C 46.98 46.27, 47.72 52.14 51.60, 52.68 0.001
LSD
# 557 1328
N 50.87 50.05, 51.69 49.72 49.18, 50.26 0.023
E 50.07 49.16, 50.98 50.06 49.54, 50.58 0.986
O 55.25 54.54, 55.96 47.80 47.27, 48.33 0.001
A 48.44 47.57, 49.31 50.68 50.16, 51.21 0.001
C 47.54 46.71, 48.36 51.12 50.59, 51.65 0.001
Methadone
# 417 1468
N 53.41 52.47, 54.35 49.11 48.61, 49.62 0.001
E 47.97 46.88, 49.05 50.66 50.17, 51.15 0.001
O 53.77 52.86, 54.69 48.93 48.42, 49.44 0.001
A 47.07 46.03, 48.10 50.86 50.37, 51.35 0.001
C 46.21 45.22, 47.20 51.15 50.66, 51.64 0.001
Magic Mushrooms
# 694 1191
N 50.73 49.98,51.47 49.67 49.10, 50.24 0.027
E 50.15 49.35,50.96 50.01 49.47, 50.55 0.765
O 54.36 53.71,55.01 47.46 46.90, 48.02 0.001
A 48.55 47.78,49.32 50.88 50.33, 51.43 0.001
C 47.54 46.81,48.27 51.53 50.97, 52.08 0.001
Nicotine
# 1264 621
N 50.97 50.41, 51.52 48.22 47.45, 48.99 0.001
E 49.98 49.41, 50.54 50.24 49.48, 50.99 0.599
O 51.47 50.92, 52.01 47.01 46.26, 47.77 0.001
A 49.20 48.65, 49.75 51.69 50.92, 52.46 0.001
C 48.64 48.08, 49.20 52.95 52.24, 53.67 0.001
VSA
# 230 1655
N 52.88 51.57, 54.20 49.67 49.19,50.15 0.001
E 48.96 47.45, 50.47 50.22 49.74,50.69 0.075
O 54.20 53.00, 55.41 49.42 48.93,49.90 0.001
A 47.30 45.92, 48.68 50.40 49.92,50.87 0.001
C 45.22 43.88, 46.56 50.73 50.26,51.20 0.001
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Table 23. Mean T-scoresample and 95% CI for it for groups of users and non-users with year based definition
Factor Users Non-users p-value
Mean T-score 95% CI for mean Mean T-score 95% CI for mean
Alcohol
# 1749 136
N 49.96 49.49, 50.43 50.55 48.87, 52.24 0.5012
E 50.12 49.64, 50.59 48.52 46.89, 50.14 0.0642
O 50.07 49.60, 50.54 49.11 47.46, 50.76 0.2712
A 49.95 49.48, 50.42 50.70 49.03, 52.37 0.3921
C 49.94 49.47, 50.41 50.73 49.03, 52.44 0.3782
Amphetamines
# 436 1449
N 52.40 51.43, 53.36 49.28 48.77, 49.78 0.0001
E 49.48 48.45, 50.50 50.16 49.66, 50.66 0.2431
O 53.83 52.92, 54.74 48.85 48.34, 49.35 0.0001
A 47.47 46.45, 48.48 50.76 50.27, 51.26 0.0001
C 45.91 44.94, 46.88 51.23 50.74, 51.72 0.0001
Amyl nitrite
# 133 1752
N 51.57 49.85, 53.29 49.88 49.41, 50.35 0.0633
E 50.25 48.44, 52.06 49.98 49.51, 50.45 0.7777
O 51.97 50.36, 53.59 49.85 49.38, 50.32 0.0136
A 46.35 44.64, 48.07 50.28 49.81, 50.74 0.0001
C 46.92 45.25, 48.60 50.23 49.77, 50.70 0.0002
Benzodiazepines
# 535 1350
N 53.69 52.84, 54.54 48.54 48.03, 49.05 0.0001
E 48.91 47.97, 49.85 50.43 49.92, 50.94 0.0053
O 53.00 52.18, 53.83 48.81 48.28, 49.34 0.0001
A 47.55 46.64, 48.46 50.97 50.46, 51.48 0.0001
C 47.06 46.19, 47.94 51.16 50.65, 51.68 0.0001
Cannabis
# 999 886
N 51.10 50.46, 51.74 48.76 48.14, 49.38 0.0001
E 49.73 49.08, 50.39 50.30 49.69, 50.91 0.2177
O 53.68 53.13, 54.23 45.85 45.22, 46.48 0.0001
A 48.77 48.13, 49.40 51.39 50.76, 52.02 0.0001
C 47.32 46.70, 47.95 53.02 52.42, 53.62 0.0001
Chocolate
# 1840 45
N 50.01 49.56, 50.47 49.45 46.04, 52.86 0.7445
E 49.99 49.53, 50.45 50.49 47.75, 53.24 0.7156
O 50.04 49.58, 50.50 48.27 45.59, 50.94 0.1945
A 50.02 49.56, 50.48 49.17 45.72, 52.62 0.6259
C 49.97 49.51, 50.42 51.41 47.81, 55.01 0.4254
Cocaine
# 417 1468
N 52.16 51.19, 53.13 49.39 48.88, 49.89 0.0001
E 50.93 49.88, 51.98 49.74 49.24, 50.23 0.0439
O 52.79 51.87, 53.71 49.21 48.70, 49.72 0.0001
Continued on the next page
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Table 23. Continued
Factor Users Non-users p-value
Mean T-score 95% CI for mean Mean T-score 95% CI for mean
A 46.84 45.81, 47.86 50.90 50.41, 51.39 0.0001
C 46.81 45.86, 47.75 50.91 50.40, 51.41 0.0001
Caffeine
# 1824 61
N 49.99 49.53, 50.45 50.36 47.75, 52.96 0.7827
E 50.10 49.64, 50.56 46.92 44.34, 49.50 0.0181
O 50.10 49.64, 50.56 47.07 44.45, 49.69 0.0265
A 49.96 49.50, 50.42 51.15 48.61, 53.69 0.3605
C 49.91 49.45, 50.37 52.79 50.14, 55.43 0.0362
Crack
# 79 1806
N 54.06 51.78, 56.35 49.82 49.36, 50.28 0.0005
E 49.24 47.20, 51.28 50.03 49.57, 50.50 0.4548
O 52.90 50.72, 55.08 49.87 49.41, 50.33 0.0084
A 46.65 44.17, 49.12 50.15 49.69, 50.61 0.0070
C 45.08 42.92, 47.25 50.22 49.76, 50.67 0.0001
Ecstasy
# 517 1368
N 50.71 49.82, 51.61 49.73 49.21, 50.25 0.0624
E 51.51 50.60, 52.42 49.43 48.91, 49.95 0.0001
O 54.10 53.32, 54.89 48.45 47.92, 48.97 0.0001
A 48.55 47.64, 49.45 50.55 50.03, 51.07 0.0002
C 47.02 46.17, 47.87 51.13 50.61, 51.65 0.0001
Heroin
# 118 1767
N 55.37 53.63, 57.12 49.64 49.18, 50.10 0.0001
E 47.68 45.68, 49.69 50.15 49.69, 50.62 0.0192
O 53.45 51.80, 55.11 49.77 49.30, 50.24 0.0001
A 44.37 42.25, 46.50 50.38 49.92, 50.83 0.0001
C 45.45 43.52, 47.39 50.30 49.84, 50.77 0.0001
Ketamine
# 208 1677
N 51.52 50.20, 52.84 49.81 49.33, 50.29 0.0175
E 51.02 49.48, 52.57 49.87 49.40, 50.34 0.1619
O 54.18 52.88, 55.49 49.48 49.00, 49.96 0.0001
A 47.90 46.42, 49.38 50.26 49.79, 50.73 0.0030
C 46.34 44.91, 47.76 50.45 49.98, 50.93 0.0001
Legal highs
# 564 1321
N 51.27 50.41, 52.12 49.46 48.93, 49.99 0.0004
E 50.02 49.11, 50.92 49.99 49.48, 50.51 0.9659
O 54.49 53.76, 55.22 48.08 47.55, 48.62 0.0001
A 48.09 47.23, 48.96 50.81 50.29, 51.34 0.0001
C 46.56 45.71, 47.41 51.47 50.95, 51.98 0.0001
LSD
# 380 1505
N 49.98 48.97, 50.99 50.00 49.50, 50.51 0.9691
Continued on the next page
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Table 23. Continued
Factor Users Non-users p-value
Mean T-score 95% CI for mean Mean T-score 95% CI for mean
E 50.72 49.63, 51.81 49.82 49.32, 50.31 0.1403
O 56.29 55.48, 57.11 48.41 47.91, 48.91 0.0001
A 49.05 47.98, 50.12 50.24 49.74, 50.74 0.0484
C 47.74 46.71, 48.77 50.57 50.07, 51.07 0.0001
Methadone
# 320 1565
N 53.74 52.65, 54.84 49.23 48.75, 49.72 0.0001
E 47.75 46.46, 49.03 50.46 49.99, 50.94 0.0001
O 53.81 52.76, 54.86 49.22 48.73, 49.71 0.0001
A 46.53 45.33, 47.73 50.71 50.23, 51.19 0.0001
C 46.01 44.87, 47.15 50.82 50.33, 51.30 0.0001
Magic Mushrooms
# 434 1451
N 50.33 49.40, 51.26 49.90 49.38, 50.42 0.4311
E 50.71 49.66, 51.76 49.79 49.29, 50.28 0.1179
O 55.72 54.96, 56.49 48.29 47.78, 48.80 0.0001
A 48.51 47.48, 49.53 50.45 49.95, 50.95 0.0009
C 47.30 46.36, 48.24 50.81 50.30, 51.32 0.0001
Nicotine
# 1060 825
N 51.16 50.55, 51.76 48.51 47.85, 49.18 0.0001
E 49.80 49.17, 50.42 50.26 49.61, 50.91 0.3094
O 51.91 51.31, 52.51 47.55 46.89, 48.20 0.0001
A 49.04 48.42, 49.65 51.24 50.58, 51.90 0.0001
C 47.98 47.38, 48.57 52.60 51.95, 53.25 0.0001
VSA
# 95 1790
N 53.81 51.67, 55.95 49.80 49.34, 50.26 0.0004
E 49.55 47.32, 51.79 50.02 49.56, 50.49 0.6832
O 53.59 51.58, 55.60 49.81 49.35, 50.27 0.0004
A 47.48 45.35, 49.61 50.13 49.67, 50.60 0.0174
C 45.31 43.18, 47.44 50.25 49.79, 50.71 0.0001
Table 24. Mean T-scoresample and 95% CI for it for groups of users and non-users with month based problem
Factor Users Non-users p-value
Mean T-score 95% CI for mean Mean T-score 95% CI for mean
Alcohol
# 1551 334
N 49.85 49.35, 50.35 50.69 49.61, 51.78 0.1669
E 50.62 50.12, 51.11 47.14 46.11, 48.17 0.0001
O 50.22 49.73, 50.72 48.96 47.87, 50.06 0.0401
A 50.10 49.60, 50.60 49.55 48.50, 50.60 0.3575
C 50.15 49.66, 50.65 49.28 48.22, 50.35 0.1460
Amphetamines
# 238 1647
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Table 24. Continued
Factor Users Non-users p-value
Mean T-score 95% CI for mean Mean T-score 95% CI for mean
N 52.78 51.49, 54.07 49.60 49.12, 50.08 0.0001
E 49.07 47.63, 50.51 50.13 49.66, 50.61 0.1665
O 52.94 51.69, 54.20 49.57 49.09, 50.06 0.0001
A 46.57 45.21, 47.92 50.50 50.02, 50.97 0.0001
C 45.06 43.75, 46.37 50.71 50.24, 51.19 0.0001
Amyl nitrite
# 41 1844
N 49.36 46.12, 52.61 50.01 49.56, 50.47 0.6911
E 49.83 46.38, 53.28 50.00 49.55, 50.46 0.9218
O 50.40 47.06, 53.74 49.99 49.53, 50.45 0.8083
A 45.43 41.87, 49.00 50.10 49.65, 50.56 0.0122
C 47.31 44.60, 50.01 50.06 49.60, 50.52 0.0490
Benzodiazepines
# 299 1586
N 55.26 54.11, 56.41 49.01 48.53, 49.48 0.0001
E 48.06 46.79, 49.33 50.37 49.89, 50.84 0.0010
O 52.68 51.59, 53.77 49.49 49.00, 49.99 0.0001
A 46.72 45.47, 47.97 50.62 50.14, 51.10 0.0001
C 46.54 45.40, 47.69 50.65 50.17, 51.14 0.0001
Cannabis
# 788 1097
N 50.72 49.99, 51.45 49.48 48.91, 50.06 0.7142
E 50.06 49.31, 50.80 49.96 49.40, 50.52 0.5738
O 54.34 53.74, 54.95 46.88 46.30, 47.46 0.3233
A 48.66 47.93, 49.38 50.97 50.39, 51.54 0.5477
C 47.26 46.55, 47.97 51.97 51.41, 52.53 0.3800
Chocolate
# 1786 99
N 49.98 49.52, 50.44 50.40 48.19, 52.60 0.0002
E 50.03 49.57, 50.49 49.43 47.38, 51.49 0.1295
O 50.05 49.58, 50.52 49.13 47.36, 50.90 0.0008
A 50.04 49.57, 50.50 49.36 47.19, 51.53 0.0001
C 49.95 49.49, 50.41 50.90 48.82, 52.97 0.0002
Cocaine
# 159 1726
N 52.87 51.29, 54.46 49.74 49.27, 50.21 0.3787
E 51.34 49.50, 53.18 49.88 49.41, 50.34 0.0078
O 52.53 51.00, 54.06 49.77 49.29, 50.24 0.0560
A 45.75 44.05, 47.46 50.39 49.93, 50.86 0.7537
C 47.23 45.71, 48.75 50.25 49.78, 50.73 0.4728
Caffeine
# 1764 121
N 50.05 49.59, 50.52 49.21 47.37, 51.05 0.0092
E 50.16 49.69, 50.63 47.68 45.93, 49.43 0.8390
O 50.12 49.65, 50.58 48.29 46.47, 50.11 0.0001
A 49.98 49.51, 50.45 50.27 48.50, 52.04 0.0001
C 49.95 49.49, 50.42 50.67 48.77, 52.56 0.0001
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Table 24. Continued
Factor Users Non-users p-value
Mean T-score 95% CI for mean Mean T-score 95% CI for mean
Crack
# 20 1865
N 57.86 52.26, 63.46 49.92 49.46, 50.37 0.1931
E 45.97 41.30, 50.64 50.04 49.59, 50.50 0.0852
O 50.89 47.21, 54.57 49.99 49.54, 50.45 0.6165
A 42.98 36.34, 49.62 50.08 49.62, 50.53 0.0380
C 45.14 40.37, 49.91 50.05 49.60, 50.51 0.0448
Ecstasy
# 240 1645
N 49.53 48.18, 50.89 50.07 49.59, 50.55 0.4649
E 52.24 50.83, 53.65 49.67 49.20, 50.15 0.0008
O 54.41 53.23, 55.59 49.36 48.88, 49.84 0.0001
A 48.10 46.75, 49.45 50.28 49.80, 50.76 0.0029
C 47.27 45.96, 48.59 50.40 49.92, 50.88 0.0001
Heroin
# 53 1832
N 56.70 54.05, 59.34 49.81 49.35, 50.26 0.0001
E 45.58 42.06, 49.10 50.13 49.67, 50.58 0.0130
O 52.48 49.63, 55.34 49.93 49.47, 50.39 0.0823
A 42.18 39.00, 45.35 50.23 49.77, 50.68 0.0001
C 43.36 40.35, 46.37 50.19 49.74, 50.65 0.0001
Ketamine
# 79 1806
N 51.29 49.14, 53.45 49.94 49.48, 50.41 0.2270
E 49.62 46.74, 52.49 50.02 49.56, 50.47 0.7851
O 54.79 52.59, 56.98 49.79 49.33, 50.25 0.0001
A 46.90 44.15, 49.66 50.14 49.68, 50.59 0.0237
C 45.03 42.50, 47.56 50.22 49.76, 50.67 0.0001
Legal highs
# 241 1644
N 52.02 50.68, 53.36 49.70 49.23, 50.18 0.0015
E 49.10 47.59, 50.61 50.13 49.66, 50.60 0.2002
O 54.37 53.22, 55.53 49.36 48.88, 49.84 0.0001
A 46.83 45.50, 48.16 50.46 49.99, 50.94 0.0001
C 45.30 44.01, 46.60 50.69 50.21, 51.16 0.0001
LSD
# 166 1719
N 50.55 48.97, 52.12 49.95 49.48, 50.42 0.4717
E 51.28 49.53, 53.04 49.88 49.41, 50.34 0.1279
O 57.28 56.16, 58.41 49.30 48.83, 49.77 0.0001
A 48.92 47.35, 50.48 50.10 49.63, 50.58 0.1533
C 47.10 45.59, 48.60 50.28 49.81, 50.75 0.0001
Methadone
# 171 1714
N 54.53 53.00, 56.06 49.55 49.08, 50.02 0.0001
E 46.86 45.07, 48.65 50.31 49.85, 50.78 0.0003
O 52.89 51.37, 54.40 49.71 49.24, 50.18 0.0001
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Table 24. Continued
Factor Users Non-users p-value
Mean T-score 95% CI for mean Mean T-score 95% CI for mean
A 46.18 44.50, 47.87 50.38 49.92, 50.85 0.0001
C 45.44 43.83, 47.05 50.45 49.99, 50.92 0.0001
Magic Mushrooms
# 159 1726
N 49.91 48.41, 51.42 50.01 49.53, 50.48 0.9064
E 50.31 48.50, 52.12 49.97 49.51, 50.44 0.7205
O 56.92 55.77, 58.07 49.36 48.89, 49.83 0.0001
A 48.57 46.94, 50.19 50.13 49.66, 50.60 0.0699
C 46.85 45.25, 48.45 50.29 49.82, 50.76 0.0001
Nicotine
# 875 1010
N 51.11 50.43, 51.79 49.04 48.44, 49.64 0.0001
E 49.98 49.29, 50.66 50.02 49.42, 50.62 0.9237
O 51.86 51.19, 52.52 48.39 47.79, 48.99 0.0001
A 49.02 48.34, 49.71 50.85 50.25, 51.44 0.0001
C 47.69 47.03, 48.34 52.01 51.41, 52.60 0.0001
VSA
# 34 1851
N 51.34 47.48, 55.20 49.98 49.52, 50.43 0.4793
E 51.80 48.00, 55.60 49.97 49.51, 50.42 0.3378
O 54.65 51.65, 57.66 49.91 49.46, 50.37 0.0032
A 45.91 42.12, 49.71 50.08 49.62, 50.53 0.0336
C 47.22 43.63, 50.81 50.05 49.60, 50.51 0.1209
Table 25. Mean T-scoresample and 95% CI for it for groups of users and non-users with week based definition
Factor Users Non-users p-value
Mean T-score 95% CI for mean Mean T-score 95% CI for mean
Alcohol
# 1264 621
N 49.82 49.28, 50.36 50.37 49.56, 51.19 0.2673
E 50.90 50.35, 51.44 48.17 47.38, 48.97 0.0001
O 50.08 49.54, 50.63 49.83 49.03, 50.62 0.6023
A 50.05 49.50, 50.60 49.89 49.09, 50.69 0.7454
C 50.19 49.64, 50.74 49.61 48.81, 50.42 0.2441
Amphetamines
# 163 1722
N 52.86 51.27, 54.45 49.73 49.26, 50.20 0.0003
E 48.50 46.78, 50.21 50.14 49.68, 50.61 0.0695
O 52.87 51.27, 54.47 49.73 49.26, 50.20 0.0003
A 46.77 45.09, 48.44 50.31 49.84, 50.77 0.0001
C 45.29 43.72, 46.85 50.45 49.98, 50.91 0.0001
Amyl nitrite
# 17 1868
N 49.64 43.98, 55.29 50.00 49.55, 50.46 0.8922
E 45.85 39.05, 52.64 50.04 49.59, 50.49 0.2106
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Table 25. Continued
Factor Users Non-users p-value
Mean T-score 95% CI for mean Mean T-score 95% CI for mean
O 49.02 43.02, 55.02 50.01 49.56, 50.46 0.7320
A 44.36 38.95, 49.77 50.05 49.60, 50.50 0.0409
C 44.81 39.74, 49.89 50.05 49.59, 50.50 0.0447
Benzodiazepines
# 179 1706
N 56.56 55.08, 58.05 49.31 48.85, 49.77 0.0001
E 46.15 44.61, 47.70 50.40 49.93, 50.87 0.0001
O 52.18 50.72, 53.64 49.77 49.30, 50.25 0.0022
A 46.57 44.94, 48.21 50.36 49.89, 50.83 0.0001
C 46.20 44.75, 47.65 50.40 49.93, 50.87 0.0001
Cannabis
# 648 1237
N 50.62 49.82, 51.42 49.68 49.13, 50.22 0.0555
E 50.17 49.36, 50.97 49.91 49.37, 50.46 0.6056
O 54.70 54.05, 55.35 47.54 46.99, 48.09 0.0001
A 48.78 48.00, 49.56 50.64 50.09, 51.19 0.0001
C 47.45 46.67, 48.23 51.34 50.80, 51.88 0.0001
Chocolate
# 1490 395
N 49.95 49.44, 50.45 50.20 49.18, 51.23 0.6601
E 50.22 49.72, 50.73 49.16 48.14, 50.17 0.0648
O 49.89 49.37, 50.40 50.42 49.48, 51.36 0.3270
A 50.20 49.70, 50.70 49.23 48.19, 50.27 0.0988
C 50.13 49.62, 50.63 49.51 48.50, 50.53 0.2864
Cocaine
# 60 1825
N 53.24 50.50, 55.99 49.89 49.44, 50.35 0.0191
E 52.03 49.22, 54.84 49.93 49.48, 50.39 0.1464
O 51.40 48.83, 53.97 49.95 49.49, 50.41 0.2727
A 43.73 40.79, 46.68 50.21 49.75, 50.66 0.0001
C 46.72 44.32, 49.11 50.11 49.65, 50.57 0.0072
Caffeine
# 1658 227
N 50.07 49.59, 50.55 49.46 48.10, 50.81 0.3998
E 50.20 49.72, 50.68 48.54 47.27, 49.81 0.0166
O 50.04 49.56, 50.52 49.71 48.40, 51.03 0.6450
A 49.93 49.45, 50.41 50.48 49.15, 51.81 0.4462
C 49.95 49.47, 50.43 50.37 49.01, 51.72 0.5690
Crack
# 11 1874
N 55.26 45.53, 64.99 49.97 49.52, 50.42 0.2540
E 46.46 38.43, 54.50 50.02 49.57, 50.47 0.3480
O 48.01 43.74, 52.28 50.01 49.56, 50.47 0.3242
A 39.61 30.12, 49.11 50.06 49.61, 50.51 0.0343
C 44.28 36.73, 51.83 50.03 49.58, 50.49 0.1211
Ecstasy
# 84 1801
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Table 25. Continued
Factor Users Non-users p-value
Mean T-score 95% CI for mean Mean T-score 95% CI for mean
N 50.28 47.99, 52.58 49.99 49.53, 50.45 0.8031
E 53.37 50.71, 56.03 49.84 49.39, 50.30 0.0110
O 56.15 54.15, 58.15 49.71 49.25, 50.17 0.0001
A 48.56 46.38, 50.75 50.07 49.61, 50.53 0.1837
C 46.98 44.78, 49.18 50.14 49.68, 50.60 0.0065
Heroin
# 29 1856
N 58.66 55.84, 61.47 49.86 49.41, 50.32 0.0001
E 44.77 39.80, 49.73 50.08 49.63, 50.53 0.0376
O 52.41 48.00, 56.81 49.96 49.51, 50.42 0.2681
A 41.48 38.25, 44.70 50.13 49.68, 50.59 0.0001
C 43.04 38.95, 47.12 50.11 49.66, 50.56 0.0015
Ketamine
# 37 1848
N 50.47 46.78, 54.16 49.99 49.54, 50.45 0.7952
E 47.23 42.01, 52.46 50.06 49.61, 50.51 0.2822
O 54.39 50.87, 57.90 49.91 49.46, 50.37 0.0148
A 44.50 40.15, 48.85 50.11 49.66, 50.56 0.0133
C 44.99 41.13, 48.85 50.10 49.65, 50.55 0.0113
Legal highs
# 131 1754
N 53.13 51.32, 54.94 49.77 49.30, 50.23 0.0005
E 47.12 45.06, 49.18 50.22 49.76, 50.67 0.0044
O 53.16 51.53, 54.79 49.76 49.30, 50.23 0.0001
A 46.25 44.62, 47.87 50.28 49.81, 50.75 0.0001
C 44.50 42.88, 46.11 50.41 49.95, 50.88 0.0001
LSD
# 69 1816
N 50.28 47.82, 52.73 49.99 49.53, 50.45 0.8196
E 52.70 49.90, 55.51 49.90 49.44, 50.35 0.0531
O 57.57 55.78, 59.35 49.71 49.25, 50.17 0.0001
A 50.03 47.88, 52.17 50.00 49.54, 50.46 0.9793
C 46.98 44.90, 49.06 50.11 49.65, 50.58 0.0045
Methadone
# 121 1764
N 54.99 53.14, 56.84 49.66 49.20, 50.12 0.0001
E 45.27 43.10, 47.43 50.32 49.87, 50.78 0.0001
O 51.87 50.02, 53.72 49.87 49.41, 50.34 0.0406
A 46.00 43.84, 48.15 50.27 49.82, 50.73 0.0002
C 45.74 43.89, 47.59 50.29 49.83, 50.76 0.0001
Magic Mushrooms
# 44 1841
N 49.79 46.82, 52.75 50.01 49.55, 50.46 0.8844
E 53.71 50.31, 57.12 49.91 49.46, 50.37 0.0309
O 57.89 55.73, 60.05 49.81 49.35, 50.27 0.0001
A 50.14 46.71, 53.57 50.00 49.54, 50.45 0.9352
C 48.03 45.33, 50.74 50.05 49.59, 50.51 0.1459
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Table 25. Continued
Factor Users Non-users p-value
Mean T-score 95% CI for mean Mean T-score 95% CI for mean
Nicotine
# 767 1118
N 51.32 50.59, 52.04 49.10 48.52, 49.67 0.0001
E 49.91 49.17, 50.65 50.06 49.49, 50.63 0.7485
O 51.57 50.85, 52.28 48.92 48.35, 49.50 0.0001
A 49.04 48.31, 49.78 50.66 50.09, 51.23 0.0007
C 47.69 46.99, 48.38 51.59 51.01, 52.16 0.0001
VSA
# 21 1864
N 50.92 46.02, 55.82 49.99 49.54, 50.44 0.6974
E 52.60 47.66, 57.53 49.97 49.52, 50.42 0.2828
O 56.30 53.63, 58.97 49.93 49.47, 50.38 0.0001
A 46.36 41.38, 51.34 50.04 49.59, 50.49 0.1407
C 49.99 45.49, 54.49 50.00 49.55, 50.45 0.9955
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S2 Appendix. PCCs between drug consumptions. In this section we show
PCCs between drug consumptions for decade and year based user/non user separation.
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Table 26. PCCs between drug consumptions with decade based user/non user separation
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Alcohol 0.0741 0.0741 0.0512 0.1191 0.0991 0.1111 0.1571 0.0274 0.1051 0.0334 0.0782 0.0612 0.0692 −0.0074 0.0711 0.1131 0.0463
Amphetamines 0.0741 0.3721 0.4631 0.4691 0.0134 0.5801 0.1061 0.3231 0.5971 0.3591 0.4121 0.4811 0.4901 0.4151 0.4811 0.3431 0.3041
Amyl nitrite 0.0741 0.3721 0.2261 0.2921 0.0284 0.3811 0.0602 0.1441 0.3921 0.1371 0.3451 0.2681 0.2131 0.0841 0.2711 0.1961 0.1301
Benzodiazepines 0.0512 0.4631 0.2261 0.3541 0.0064 0.4281 0.0552 0.3261 0.3831 0.3951 0.3031 0.3481 0.3521 0.4681 0.3661 0.2601 0.2941
Cannabis 0.1191 0.4691 0.2921 0.3541 0.0463 0.4531 0.1131 0.2161 0.5211 0.2171 0.3021 0.5261 0.4211 0.2991 0.4971 0.5331 0.2371
Chocolate 0.0991 0.0134 0.0284 0.0064 0.0463 0.0064 0.1221 0.0324 0.0404 −0.0264 0.0354 0.0174 0.0294 0.0074 0.0244 0.0374 −0.0214
Cocaine 0.1111 0.5801 0.3811 0.4281 0.4531 0.0064 0.0991 0.3961 0.6331 0.4141 0.4541 0.4451 0.4421 0.3541 0.4801 0.3621 0.2771
Caffeine 0.1571 0.1061 0.0602 0.0553 0.1131 0.1221 0.0991 0.0354 0.1071 0.0264 0.0583 0.0851 0.0751 0.0394 0.1001 0.1453 0.0533
Crack 0.0274 0.3231 0.1441 0.3261 0.2161 0.0324 0.3961 0.0354 0.2801 0.5091 0.2551 0.2031 0.2681 0.3671 0.2761 0.1911 0.2781
Ecstasy 0.1051 0.5971 0.3921 0.3831 0.5211 0.0404 0.6331 0.1071 0.2801 0.3011 0.5111 0.5861 0.5991 0.3151 0.5991 0.3701 0.2891
Heroin 0.0334 0.3591 0.1371 0.3951 0.2171 −0.0264 0.4141 0.0264 0.5091 0.3011 0.2741 0.2371 0.3471 0.4941 0.3061 0.1851 0.2931
Ketamine 0.0781 0.4121 0.3451 0.3031 0.3021 0.0354 0.4541 0.0583 0.2551 0.5111 0.2741 0.3931 0.4621 0.2461 0.4361 0.2431 0.1921
Legal highs 0.0612 0.4811 0.2681 0.3481 0.5261 0.0174 0.4451 0.0851 0.2031 0.5861 0.2371 0.3931 0.5191 0.3341 0.5751 0.3641 0.3141
LSD 0.0692 0.4901 0.2131 0.3521 0.4211 0.0294 0.4421 0.0751 0.2681 0.5991 0.3471 0.4621 0.5191 0.3431 0.6801 0.2891 0.2991
Methadone −0.0074 0.4151 0.0841 0.4681 0.2991 0.0074 0.3541 0.0394 0.3671 0.3151 0.4941 0.2461 0.3341 0.3431 0.3431 0.2341 0.2771
MMushrooms 0.0711 0.4811 0.2711 0.3661 0.4971 0.0244 0.4801 0.1001 0.2761 0.5991 0.3061 0.4361 0.5751 0.6801 0.3431 0.3241 0.2531
Nicotine 0.1131 0.3431 0.1961 0.2601 0.5331 0.0374 0.3621 0.1451 0.1911 0.3701 0.1851 0.2431 0.3641 0.2891 0.2341 0.3241 0.2211
VSA 0.0463 0.3041 0.1301 0.2941 0.2371 −0.0214 0.2771 0.0533 0.2781 0.2891 0.2931 0.1921 0.3141 0.2991 0.2771 0.2531 0.2211
Note: 1p-value< 0.001, 2p-value< 0.01, 3p-value< 0.05, 4p-value> 0.05. p-value is the probability to observe by chance the same or greater correlation for uncorrelated variables.
Table 27. PCCs between drug consumptions with year based user definition
D
r
u
g
A
l
c
o
h
o
l
A
m
p
h
e
t
a
m
i
n
e
s
A
m
y
l
n
i
t
r
i
t
e
B
e
n
z
o
d
i
a
z
e
p
i
n
e
s
C
a
n
n
a
b
i
s
C
h
o
c
o
l
a
t
e
C
o
c
a
i
n
e
C
a
ff
e
i
n
e
C
r
a
c
k
E
c
s
t
a
s
y
H
e
r
o
i
n
K
e
t
a
m
i
n
e
L
e
g
a
l
h
i
g
h
s
L
S
D
M
e
t
h
a
d
o
n
e
M
M
u
s
h
r
o
o
m
s
N
i
c
o
t
i
n
e
V
S
A
Alcohol 0.0464 0.0613 0.0482 0.0783 0.0771 0.1241 0.1111 0.0581 0.1071 0.0301 0.0724 0.0931 0.0841 −0.0051 0.0754 0.0811 0.0553
Amphetamines 0.0463 0.2221 0.4361 0.4211 0.0034 0.4531 0.0722 0.1931 0.4611 0.3051 0.3251 0.4711 0.3921 0.3821 0.3751 0.3111 0.1731
Amyl nitrite 0.0612 0.2221 0.1991 0.1851 0.0164 0.2621 0.0503 0.0771 0.2761 0.1001 0.2801 0.2771 0.1201 0.0911 0.1591 0.1391 0.1071
Benzodiazepines 0.0483 0.4361 0.1991 0.3341 −0.0094 0.3651 0.0622 0.2321 0.3041 0.3181 0.2631 0.3181 0.2121 0.4641 0.2711 0.2611 0.1831
Cannabis 0.0781 0.4211 0.1851 0.3341 0.0204 0.3921 0.0742 0.1651 0.4841 0.1991 0.2771 0.5161 0.4331 0.3011 0.4701 0.5171 0.1641
Chocolate 0.0771 0.0034 0.0164 −0.0094 0.0204 0.0084 0.0891 −0.0374 0.0573 −0.0034 0.0004 0.0264 0.0444 0.0064 0.0194 0.0094 −0.0124
Cocaine 0.1241 0.4531 0.2621 0.3651 0.3921 0.0084 0.0692 0.3221 0.5351 0.3581 0.3791 0.3941 0.3021 0.3141 0.3461 0.3291 0.1871
Caffeine 0.1111 0.0722 0.0503 0.0622 0.0742 0.0891 0.0692 0.0234 0.0593 0.0234 0.0264 0.0673 0.0324 0.0274 0.0503 0.1051 0.0424
Crack 0.0583 0.1931 0.0771 0.2321 0.1651 −0.0374 0.3221 0.0234 0.1561 0.3501 0.1801 0.1471 0.1391 0.2651 0.1811 0.1261 0.1451
Ecstasy 0.1071 0.4611 0.2761 0.3041 0.4841 0.0573 0.5351 0.0591 0.1561 0.1901 0.4551 0.5021 0.5091 0.2451 0.4801 0.3431 0.1741
Heroin 0.0304 0.3051 0.1001 0.3181 0.1991 −0.0034 0.3581 0.0234 0.3501 0.1901 0.2171 0.1851 0.1701 0.3851 0.1711 0.1491 0.1211
Ketamine 0.0722 0.3251 0.2801 0.2631 0.2771 0.0004 0.3791 0.0264 0.1801 0.4551 0.2171 0.3731 0.3511 0.2021 0.3621 0.2221 0.1511
Legal highs 0.0931 0.4711 0.2771 0.3181 0.5161 0.0264 0.3941 0.0672 0.1471 0.5021 0.1851 0.3731 0.4341 0.3091 0.4851 0.3481 0.2201
LSD 0.0841 0.3921 0.1201 0.2121 0.4331 0.0444 0.3021 0.0324 0.1391 0.5091 0.1701 0.3511 0.4341 0.2341 0.6271 0.2671 0.1741
Methadone −0.0054 0.3821 0.0911 0.4641 0.3011 0.0064 0.3141 0.0274 0.2651 0.2451 0.3851 0.2021 0.3091 0.2341 0.2531 0.2111 0.1671
MMushrooms 0.0752 0.3751 0.1591 0.2711 0.4701 0.0194 0.3461 0.0503 0.1811 0.4801 0.1711 0.3621 0.4851 0.6271 0.2531 0.2821 0.1741
Nicotine 0.0811 0.3111 0.1391 0.2611 0.5171 0.0094 0.3291 0.1051 0.1261 0.3431 0.1491 0.2221 0.3481 0.2671 0.2111 0.2821 0.1451
VSA 0.0553 0.1731 0.1071 0.1831 0.1641 −0.0124 0.1871 0.0424 0.1451 0.1741 0.1211 0.1511 0.2201 0.1741 0.1671 0.1741 0.1451
Note: 1p-value< 0.001, 2p-value< 0.01, 3p-value< 0.05, 4p-value> 0.05. p-value is the probability to observe by chance the same or greater correlation for uncorrelated variables.
6
0
References
1. Kleiman MA, Caulkins JP, Hawken A. Drugs and Drug Policy: What
Everyone Needs to Know. Oxford University Press; 2011.
2. McGinnis JM, Foege WH. Actual causes of death in the United States. Journal
of the American Medical Association. 1993; 270(18):2207–2212.
3. Sutina AR, Evans MK, Zonderman AB. Personality traits and illicit
substances: the moderation role of poverty. Drug and Alcohol Dependence.
2013; 131:247–251.
4. Cleveland MJ, Feinberg ME, Bontempo DE, Greenberg MT. The role of risk
and protective factors in substance use across adolescence. Journal of
Adolescent Health. 2008; 43(2):157–164.
5. Ventura CA, de Souza J, Hayashida M, Ferreira PS. Risk factors for
involvement with illegal drugs: opinion of family members or significant others.
Journal of Substance Use. 2014; 20(2):136–142.
6. WHO. Prevention of mental disorders: Effective interventions and policy
options: Summary report. Geneva: World Health Organization; 2004.
Available:
http://www.who.int/mental_health/evidence/en/prevention_of_mental_disorders
7. Dubey C, Arora M, Gupta S, Kumar B. Five factor correlates: A comparison
of substance abusers and non-substance abusers. Journal of the Indian
Academy of Applied Psychology. 2010; 36(1):107–114.
8. Bogg T, Roberts BW. Conscientiousness and health-related behaviors: A
meta-analysis of the leading behavioral contributors to mortality. Psychological
Bulletin. 2004; 130(6):887.
9. Beaglehole R, Bonita R, Horton R, Adams C, Alleyne G, Asaria P, Baugh V,
Bekedam H, Billo N, Casswell S, et al. Priority actions for the
non-communicable disease crisis. The Lancet. 2011; 377(9775):1438–1447.
10. Bickel WK, Johnson MW, Koffarnus MN, MacKillop J, Murphy G James. The
behavioral economics of substance use disorders: reinforcement pathologies and
their repair. Annual review of clinical psychology. 2014; 10:641–677.
11. Costa PT, MacCrae RR. Revised NEO-Personality Inventory (NEO PI-R) and
NEO Five-Factor Inventory (NEO FFI): Professional manual. Odessa, FL:
Psychological Assessment Resources; 1992.
12. Roncero C, Daigre C, Barral C, Ros-Cucurull E, Grau-Lo´pez L,
Rodr´ıguez-Cintas L, Tarifa N, Casas M, Valero S. Neuroticism associated with
cocaine-induced psychosis in cocaine-dependent patients: a cross-sectional
observational study. PloS one. 2014; 9(9):e106,111.
13. Vollrath M, Torgersen S. Who takes health risks? a probe into eight personality
types. Personality and Individual Differences. 2002; 32(7):1185–1197.
14. Flory K, Lynam D, Milich R, Leukefeld C, Clayton R. The relations among
personality, symptoms of alcohol and marijuana abuse, and symptoms of
comorbid psychopathology: results from a community sample. Experimental
and Clinical Psychopharmacology. 2002; 10(4):425–434.
61
15. Andreassen CS, Griffiths MD, Gjertsen SR, Krossbakken E, Kvam S, Pallesen
S. The relationships between behavioral addictions and the five-factor model of
personality. Journal of Behavioral Addictions. 2013; 2(2): 90–99.
16. Terracciano A, Lo´ckenhoff CE, Crum RM, Bienvenu OJ, Costa PT. Five-Factor
Model personality profiles of drug users. Bmc Psychiatry. 2008; 8(1):22.
17. Turiano NA, Whiteman SD, Hampson SE, Roberts BW, Mroczek DK.
Personality and substance use in midlife: Conscientiousness as a moderator
and the effects of trait change. Journal of research in personality. 2012;
46(3):295–305.
18. Stewart SH, Devine H. Relations between personality and drinking motives in
young adults. Personality and Individual Differences. 2000; 29(3):495–511.
19. Haider AH, Edwin DH, MacKenzie EJ, Bosse MJ, Castillo RC, Travison TG,
Group LS, et al. The use of the NEO-Five Factor inventory to assess
personality in trauma patients: a two-year prospective study. Journal of
Orthopaedic trauma. 2002; 16(9):660–667.
20. Belcher AM, Volkow ND, Moeller FG, Ferre´ S, Personality traits and
vulnerability or resilience to substance use disorders, Trends in cognitive
sciences. 2016; 18(4):2
21. Kopstein AN, Crum RM, Celentano DD, Martin SS. Sensation seeking needs
among 8th and 11th graders: characteristics associated with cigarette and
marijuana use. Drug and alcohol dependence. 2001; 62(3):195–203.
22. Yasnitskiy L, Gratsilev V, Kulyashova J, Cherepanov F. Possibilities of
artificial intellect in detection of predisposition to drug addiction. Perm
University Herald Series “Philosophy Psychology Sociology”. 2015; 1(21):61–73.
23. Valero S, Daigre C, Rodr´ıguez-Cintas L, Barral C, Goma`-i-Freixanet M, Ferrer
M, Casas M, Roncero C. Neuroticism and impulsivity: Their hierarchical
organization in the personality characterization of drug-dependent patients
from a decision tree learning perspective. Comprehensive Psychiatry. 2014;
55(5):1227–1233.
24. Bulut F, Bucak IO¨. An urgent precaution system to detect students at risk of
substance abuse through classification algorithms. Turkish Journal of Electrical
Engineering & Computer Sciences. 2014; 22(3):690–707.
25. Rioux C, Castellanos-Ryan N, Parent S, Se´gu JR, The interaction between
temperament and the family environment in adolescent substance use and
externalizing behaviors: Support for diathesis–stress or differential
susceptibility? Developmental Review. 2016; 40: 117–150.
26. Weissman DG, Schriber RA, Fassbender C, Atherton O, Krafft C, Robins RW,
Hastings PD, Guyerb AE, Earlier adolescent substance use onset predicts
stronger connectivity between reward and cognitive control brain networks.
Developmental Cognitive Neuroscience. 2015; 16:121–129.
27. Fehrman E, Egan V. Drug consumption, collected online March 2011 to March
2012, English-speaking countries. ICPSR36536-v1. Ann Arbor, MI:
Inter-university Consortium for Political and Social Research [distributor],
2016-09-09. Deposited by Mirkes E. http://doi.org/10.3886/ICPSR36536.v1
62
28. McCrae RR, Costa PT. A contemplated revision of the NEO Five-Factor
Inventory. Personality and Individual Differences. 2004; 36(3):587–596.
29. Stanford MS, Mathias CW, Dougherty DM, Lake SL, Anderson NE, Patton
JH. Fifty years of the Barratt Impulsiveness Scale: An update and review.
Personality and Individual Differences. 2009; 47(5):385–395.
30. Zuckerman M. Behavioral expressions and biosocial bases of sensation seeking.
New York: Cambridge University Press; 1994.
31. Bruinsma K, Taren DL. Chocolate: food or drug? Journal of the American
Dietetic Association. 1999; 99(10):1249–1256.
32. Fehrman E, Muhammad AK, Mirkes EM, Egan V, Gorban AN. The Five
Factor Model of personality and evaluation of drug consumption risk. ArXiv
preprint, version 1 https://arxiv.org/abs/1506.06297v1. 2015.
33. Egan V, Deary I, Austin E. The NEO-FFI: Emerging British norms and an
item-level analysis suggest N, A and C are more reliable than O and E.
Personality and Individual Differences. 2000; 29(5):907–920.
34. Gurrera RJ, Nestor PG, O’Donnell BF. Personality traits in schizophrenia:
comparison with a community sample. The Journal of Nervous and Mental
Disease. 2000; 188(1):31–35.
35. Terentjev PV. Biometrische Untersuchungen ’´Uber Die Morpho-Logischen
Merkmale Von Rana Ridibunda Pall:(Amphibia, Salientia). Biometrika. 1931;
1:23–51. Available: http://www.jstor.org/stable/2333629
36. Mitteroecker P, Bookstein F. The conceptual and statistical relationship
between modularity and morphological integration. Systematic biology. 2007;
56(5):818-836.
37. Berg RL. The ecological significance of correlation pleiades. Evolution. 1960;
1:171-180. Available: http://www.jstor.org/stable/2405824
38. Armbruster WS, Di Stilio VS, Tuxill JD, Flores TC, Runk JL. Covariance and
decoupling of floral and vegetative traits in nine Neotropical plants: a
re-evaluation of Berg’s correlation-pleiades concept. American Journal of
Botany. 1999; 86(1):39–55.
39. Krishnapuram R, Keller JM. A possibilistic approach to clustering. IEEE
transactions on fuzzy systems. 1993; 1(2):98–110.
40. Bezdek, J. Pattern recognition with fuzzy objective function algorithms. New
York, NY: Plenum Press; 1981.
41. Xu R, Wunsch D. Clustering. Hoboken, New Jersey: John Wiley & Sons Inc.;
2008.
42. Omote H, Sugiyama K. Method for drawing intersecting clustered graphs and
its application to web ontology language. In Proceedings of the 2006
Asia-Pacific Symposium on Information Visualisation-Volume 60 2006 Jan 1
(pp. 89-92). Australian Computer Society, Inc. Available:
http://citeseerx.ist.psu.edu/viewdoc/download?doi=10.1.1.294.2209&rep=rep1&
43. Hoare J, Moon D. (eds.) Drug misuse declared: findings from the 2009/10.
British Crime Survey Home Office Statistical Bulletin 13/10; 2010. Available:
https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/1
63
44. Egan V. Individual differences and antisocial behaviour. In: Furnham A,
Stumm S, Petredies K, editors. Handbook of Individual Differences. Oxford:
Blackwell-Wiley; 2011. pp. 512–537.
45. McCrae RR, Costa PT. The NEO Personality Inventory: Using the
Five-Factor model in counseling. Journal of Counseling & Development. 1991;
69(4):367–372.
46. Jakobwitz S, Egan V. The dark triad and normal personality traits.
Personality and Individual Differences. 2006; 40(2):331–339.
47. Settles RE, Fischer S, Cyders MA, Combs JL, Gunn RL, Smith GT. Negative
urgency: a personality predictor of externalizing behavior characterized by
neuroticism, low conscientiousness, and disagreeableness. Journal of Abnormal
Psychology. 2012; 121(1):160–172.
48. Snowden RJ, Gray NS. Impulsivity and psychopathy: Associations between
the barrett impulsivity scale and the psychopathy checklist revised. Psychiatry
Research. 2011; 187(3):414–417.
49. Garc´ıa-Montes JM, Zald´ıvar-Basurto F, Lo´pez-Rı´os F, Molina-Moreno A. The
role of personality variables in drug abuse in a Spanish university population.
International journal of mental health and addiction. 2009; 7(3):475–487.
50. Fossati P, Ergis AM, Allilaire JF. Problem-solving abilities in unipolar
depressed patients: comparison of performance on the modified version of the
Wisconsin and the California sorting tests. Psychiatry Research. 2001;
104(2):145–156.
51. McDaniel SR, Mahan JE. An examination of the Impss scale as a valid and
reliable alternative to the SSS-V in optimum stimulation level research.
Personality and Individual Differences. 2008; 44(7):1528–1538.
52. Ragan DT, Beaver KM. Chronic Offenders: A Life-Course Analysis of
Marijuana Users. Youth & Society. 2010; 42:174–198.
53. HomeOfficeUK. Drug misuse:findings from the 2013 to 2014 CSEW 2nd ed.
2014. Available:
https://www.gov.uk/government/statistics/drug-misuse-findings-from-the-201
54. Fridberg DJ, Vollmer JM, O’Donnell BF, Skosnik PD. Cannabis users differ
from non-users on measures of personality and schizotypy. Psychiatry Research.
2011; 186(1):46–52.
55. Lee SY, Poon WY, Bentler PM. A two-stage estimation of structural equation
models with continuous and polytomous variables. British Journal of
Mathematical and Statistical Psychology. 1995; 48(2):339–358.
56. Martinson EO, Hamdan MA. Maximum likelihood and some other
asymptotically efficient estimators of correlation in two way contingency tables.
Journal of Statistical Computation and Simulation. 1971; 1(1):45–54.
57. Linting M, van der Kooij A. Nonlinear Principal Components Analysis with
CATPCA: A tutorial. Journal of Personality Assessment. 2012; 94(1):12–25.
58. Gorban AN, Zinovyev AY. Principal graphs and manifolds. In: Olivas ES,
Guerrero JDM, Sober MM, Benedito JRM, Lo´pez AJS, editors. Handbook of
Research on Machine Learning Applications and Trends: Algorithms, Methods,
and Techniques. Hershey – New York. IGI Global; 2009. pp. 28–59.
64
59. Gorban AN, Zinovyev AY. Principal manifolds and graphs in practice: from
molecular biology to dynamical systems. International journal of neural
systems. 2010; 20(03):219–232.
60. Gorban AN, Ke´gl B, Wunsch DC, Zinovyev AY (eds). Principal Manifolds for
Data Visualisation and Dimension Reduction. LNCSE, Vol. 58,
Berlin-Heidelberg-New York. Springer; 2008.
61. Pearson K. On lines and planes of closest fit to system of points in space.
Philosophical magazine. 1901; 2(6):559–572.
62. Guttman L. Some necessary conditions for common-factor analysis.
Psychometrika. 1954; 19(2):149–161.
63. Kaiser HF. The application of electronic computers to factor analysis.
Educational and Psychological Measurement. 1960; 20:141–151.
64. Gujarati DN. Basic econometrics, 4th ed. New York: McGraw-Hill; 2003.
65. McCabe GP. Principal variables. Technometrics. 1984; 26(2):137–144.
66. Naikal N, Yang AY, Sastry SS. Informative feature selection for object
recognition via Sparse PCA. In: Computer Vision (ICCV), 2011 IEEE
International Conference on, IEEE; 2011. pp. 818–825. doi:
10.1109/ICCV.2011.6126321
67. Clarkson KL. Nearest-neighbor searching and metric space dimensions. In:
Shakhnarovich G, Darrell T, Indyk P, editors. Nearest-neighbor methods for
Learning and Vision: Theory and Practice. MIT Press; 2006. pp. 15–59.
68. Fisher RA. The use of multiple measurements in taxonomic problems. Annals
of Eugenics. 1936; 7(2):179–188.
69. Hastie T, Tibshirani R. Discriminant adaptive nearest neighbor classification.
Pattern Analysis and Machine Intelligence, IEEE Transactions on. 1996;
18(6):607–616.
70. Li Q, Racine JS. Nonparametric econometrics: theory and practice. Princeton
University Press; 2007.
71. Breiman L, Friedman J, Stone CJ, Olshen RA. Classification and regression
trees. Belmont, Calif: Wadsworth International Group; 1984.
72. Quinlan JR. Simplifying decision trees. International Journal of Man-Machine
Studies. 1987; 27(3):221–234.
73. Rokach L, Maimon O. Decision trees. In: Rokach L, Maimon O, editors. Data
Mining and Knowledge Discovery Handbook. Berlin: Springer; 2010. pp.
165–192.
74. Sofeikov KI, Tyukin IY, Gorban AN, Mirkes EM, Prokhorov DV, Romanenko
IV. Learning optimization for decision tree classification of non-categorical
data with information gain impurity criterion. In: Neural Networks (IJCNN);
2014. Interna. Joint Confe. on, IEEE; 2014. pp. 3548–3555.
75. Gelfand SB, Ravishankar CS, Delp EJ. An iterative growing and pruning
algorithm for classification tree design. IEEE Transaction on Pattern Analysis
and Machine Intelligence. 1991; 13(2):163–174.
65
76. Dietterich T, Kearns M, Mansour Y. Applying the weak learning framework to
understand and improve C4.5. In: ICML, Proc. of the 13th Int. Conf. on
Machine Learning. San Francisco: Morgan Kaufmann; 1996. pp. 96–104.
77. Kearns M, Mansour Y. On the boosting ability of top-down decision tree
learning algorithms. Journal of Computer and System Sciences. 1999;
58(1):109–128.
78. Dinov ID. Expectation Maximization and Mixture Modeling Tutorial. UCLA,
Statistics Online Computational Resource; 2008. Available:
http://escholarship.org/uc/item/1rb70972.
79. Buhmann MD. Radial basis functions: theory and implementations, vol 12.
Cambridge: University Press; 2003.
80. Scott DW. Multivariate Density Estimation: Theory, Practice, and
Visualization, 1st edn. New York: Wiley; 1992.
81. Hosmer Jr DW, Lemeshow S. Applied logistic regression. John Wiley & Sons;
2004.
82. Russell S, Norvig P. Artificial intelligence: a modern approach; 1995.
83. Breiman L. Random Forests. Machine Learning. 2001; 45(1):5–32.
84. Biau G. Analysis of a random forests model. The Journal of Machine Learning
Research. 2012; 13(1):1063–1095.
85. Hastie T, Tibshirani R, Friedman J. The elements of statistical learning. New
York: Springer; 2009.
86. Liaw A, Wiener MR. Classification and Regression by randomForest. R news.
2002; 2(3):18–22.
87. Williams G. Data Mining with Rattle and R: The Art of Excavating Data for
Knowledge Discovery. Springer Science & Business Media; 2011.
88. Arlot S, Celisse A. A survey of cross-validation procedures for model selection.
Statistics surveys. 2010; 4:40–79.
89. Benjamini Y, Hochberg Y. Controlling the false discovery rate: a practical and
powerful approach to multiple testing. Journal of the Royal Statistical Society.
1995; 57(1):289–300.
90. Mitchell TM. Machine learning. 1997. Burr Ridge, IL: McGraw Hill 45; 1997.
91. Mirkes EM, Alexandrakis I, Slater K, Tuli R, Gorban AN. Computational
diagnosis and risk evaluation for canine lymphoma. Computers in Biology and
Medicine. 2014a; 53:279–290.
92. Mirkes EM, Alexandrakis I, Slater K, Tuli R, Gorban AN. Computational
diagnosis of canine lymphoma. Journal of Physics: Conference Series. 2014;
490(1):012135. Available:
http://stacks.iop.org/1742-6596/490/i=1/a=012135.
93. Wilmoth DR. Intelligence and past use of recreational drugs. Intelligence. 2012;
40(1):15–22.
66
94. Jones SP, Heaven PCL, Psychosocial correlates of adolescent drug-taking
behaviour. Journal of Adolescence. 1998; 21(2): 127–134.
95. Whiteside SP, Lynam DR. The five factor model and impulsivity: Using a
structural model of personality to understand impulsivity. Personality and
Individual Differences. 2001; 30:669–689.
96. Gibbons S. ‘Legal Highs’–novel and emerging psychoactive drugs: a chemical
overview for the toxicologist. Clinical Toxicology. 2012; 50:15–24.
97. Nutt D, King LA, Saulsbury W, Blakemore C. Development of a rational scale
to assess the harm of drugs of potential misuse. The Lancet. 2007;
369:1047–1053.
98. Digman JM. Higher-order factors of the Big Five. Journal of Personality and
Social Psychology. 1997; 73:1246–1256.
99. DeYoung CG, Peterson JB, Higgins DM. Higher-order factors of the Big Five
predict conformity: Are there neuroses of health?. Personality and Individual
Differences. 2002; 33:533–552.
100. DeYoung CG, Peterson JB, Se´guin JR, Tremblay RE. Externalizing behavior
and the higher order factors of the Big Five. Journal of Abnormal Psychology.
2008; 117:947–953.
67
